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Abstract 
 
The  evidence  in  the  detection  of  blood  doping  among  endurance  athletes  is 
conflicting  especially  when  these  athletes  are  undergoing  autologous  blood 
transfusions  and  abusing  recombinant  human  erythropoietin  (rHuEPO). 
Continuous  monitoring  all  year  round  and  creating  haematological  profiles, 
known  as  athlete’s  haematological  or  blood  passport  with  cut-off  values, are 
being practiced by some international sport federations to ban athletes from 
participating or apply sanctions and punishments when the tested athletes are 
proven  to  be  doped.  However,  athletes  who  use  prohibited  substances  or 
methods  that  increase  the  concentration  of  red  blood  cells  and  haemoglobin 
(Hb)  are  also  using  masking  agents  and  other  methods  to  manipulate  the 
samples.  The  use  of  plasma  expanders  are  prohibited  as  they  induce 
haemodilution and can potentially result in false negatives of athletes’ blood 
samples. Other substances to date, specifically the ingestion of Creatine (Cr) 
and Glycerol (Gly), can cause plasma expansion when taken together by their 
novel synergistic effect on the human body and particularly on total body water 
(TBW).  However,  Gly  has  recently  been  added  to  the  WADA  2010  prohibited 
substances list (following the completion and publication of some of the results 
from the experiments presented here). In addition, the posture of the sampled 
athlete during blood collection may also influence the concentration of blood 
parameters and potentially plasma volume. The main objectives of the studies 
presented in this thesis are to test the hypothesis that the use of hyperhydration 
agents, particularly Cr and Gly, in conjunction with postural changes will dilute 
blood samples to the extent that this manipulation could potentially influence 
the results of a blood doping test. 
 
In the first experiment (EXP1), eight subjects volunteered to take part in Cr and 
Gly fluid loading for 7 days. Urine samples and body mass were obtained before 
subjects lay in a supine (0°) postural position for 30 min. During that period, 
body water compartments were estimated and urine and blood samples were 
obtained from the subjects. This hyperhydration strategy and posture resulted in 
a significant increase in body mass by 0.82 ± 0.22 kg, TBW by 0.67 ± 0.17 L, 
intracellular water (ICW) by 0.35 ± 0.09 L, extracellular water (ECW) by 0.37 ±  
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0.15 L and urine osmolality by 161 ± 115 mOsmol.kg
-1 (P<0.05) with significant 
decreases  in  Haematocrit  (Hct)  values  at  10  min,  20  min  and  30  min  blood 
samples by 1.26% ± 0.65%, 1.3% ± 0.96% , 1.35% ± 0.73%, respectively, (P<0.05) 
and an insignificant decease in Hb concentration (P=0.07). These results showed 
that  the  fluid  loading  protocol  and  posture  used  induced  a  degree  of 
hyperhydration and haemodilution that could potentially influence the outcome 
of a drug test.  
 
The  second  experiment  (EXP2)  focused  on  the  changes  in  Hb  and  Hct  with 
different postural positions of ten euhydrated subjects. The extensive research 
done to detect blood doping by indirect markers and equations used the supine 
postural  position  for  5-10  min  prior  to  obtaining  blood  samples.  However, 
WADA’s  only  approved  postural  position  is  to  have  the  selected  athlete, 
undergoing a doping test, be seated for 10 min before venipuncture. However, 
most  of  WADA’s  anti-doping  research  relating  to  this  application  have  been 
based  on  tests  developed  with  subjects  tested  in  a  supine  position.  In  this 
experiment,  three  postural  positions  were  applied:  Supine  (0°),  sitting  and 
standing. As subjects changed their postures from supine (0°), sitting and ending 
with standing, there was an increased haemoconcentration as reflected by an 
increase  in  Hb  and  Hct  values  (P<0.05).  Hb  concentration  and  Hct  values 
increased by 0.55 ± 0.06 g.L
-1 and 0.87% ± 0.12%, respectively, when subjects 
changed their posture from supine to sitting and increased by 0.71 ± 0.14 g.L
-1 
and  1.70%  ±  0.08%,  respectively,  when  subjects  changed  their  posture  from 
sitting to standing. This experiment showed that the posture in which the blood 
samples  were  obtained  from  human  subjects  has  a  direct  effect  on  the 
concentration of blood parameters such as Hb and Hct. While not a new finding, 
this  observation  confirmed  the  idea  that  posture  requires  standardisation  for 
meaningful  research  outcomes  aimed  at  developing  valid  doping  tests  to  be 
developed (currently not the case).  
 
In the third experiment (EXP3), seven healthy trained subjects volunteered to 
take part in Cr and Gly hyperhydration followed by 2 running bouts at 60% of 
their  maximum  oxygen  uptake  (VO2  max)  in  an  environmental  chamber.  This 
experiment employed a different Cr and Gly hyperhydration strategy to the one 
used in EXP1. Specifically, Cr was loaded for 7 days and Gly was only ingested on  
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the day of experiment and precisely 5 hours prior to the first blood sample. Each 
exercise bout consisted of 30 min running bouts but at two different climatic 
temperatures 10°C and 35°C, respectively with 70% relative humidity. Body mass 
and urine samples were taken before the start of the test. Blood samples were 
obtained after the subjects were comfortably seated for 10 min and just prior to 
the start of the test as well as after each running bout. This protocol resulted in 
no significant changes in Hb, Hct, Reticulocytes (Retics%) and OFF-hr scores and 
values. In general this revised hyperhydration regiment did not induce the same 
degree of haemodilution and plasma expansion as the previous approach and 
could therefore account for the negative findings on blood profiles.  
 
The hyperhydration protocol of EXP1 using Cr and Gly for 7 days succeeded in 
significantly manipulating and increasing body mass, TBW, ICW, ECW and urine 
osmolality (P<0.05) and decreasing Hct (P<0.05) values but not Hb concentration 
(P=0.07) when blood was withdrawn in supine (0°) posture. In EXP2, the change 
of  posture  from  supine  (0°),  to  sitting  and  ending  with  standing  resulted  in 
haemoconcentration and increases in Hct and Hb values. With a slight change of 
hyperhydration protocol in EXP3 of Cr for 7 days and Gly on the seventh day 
only, it resulted in no significant changes in Hct, Hb, %Retics and OFF-hr scores 
and therefore no haemodilution effects when compared to pre-supplementation 
tests  at  rest  and  following  submaximal  exercise  bouts  in  cool  and  warm 
environments. In all EXP1, EXP2 and EXP3, Hct among other blood parameters 
was  the  most  affected  by  hyperhydration,  posture  and  time  at  which  blood 
samples  were  obtained.  The  hyperhydration  protocol  of  EXP1  was  more 
successful in decreasing Hct and Hb values than EXP3.  
 
More research should be focused on determining whether the extent of blood 
dilution induced by hyperhydration strategies such as those used in the present 
series  of  experiments  can  alter  the  outcome  of  a  doping  test.  Other 
hyperhydration/fluid  loading  protocols  should  be  assessed  including  plasma 
expanding substances and methods in view of these substances being considered 
by WADA to be included in the prohibited substances and methods list (if proven 
effective). It is recommended that the emphasis of WADA-related research is 
also shifted to the identification of other physiological/molecular markers that 
are  not  significantly  affected  by  haemodilution  such  genetic  signatures  in  
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response to drug perturbations (e.g. autologous blood transfusions and rHuEPO 
injections).  
 
 
 
Key  words:  Doping,  Blood  Doping,  erythropoietin  (EPO),  erythropoiesis, 
recombinant  human  erythropoietin  (rHuEPO),  urine  tests,  blood  transfusions, 
blood tests, haemoglobin (Hb), haematocrit (Hct), reticulocytes (Retics%), OFF-
hr  score,  plasma  expansion,  hyperhydration,  haemodilution,  Creatine  (Cr), 
Glycerol (Gly).  
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1. General Introduction 
1.1. Doping Definition    
 
According to the International Olympic Committee (IOC), Doping is defined as 
“the  use  of  physiological  substances  in  abnormal  amounts  and  with 
abnormal  methods,  with  the  exclusive  aim  of  attaining  an  artificial  and 
unfair increase of performance in competition” (Dugal and Bertrand, 1976;  as 
cited  by  Wilber,  2002).  However,  after  the  2000  Olympic  Games,  The  World 
Anti-Doping Agency (WADA) established the World Anti-Doping Code 2003 and 
added some other specifications to the word “Doping” rather than the attempt 
to use a prohibited substance or a prohibited method. WADA considers Doping as 
the violation of the World Anti-Doping Code rules by the incidence of one or 
more than one aspect; “Doping is defined as the occurrence of one or more of 
the anti-doping rule violations set forth in Article 2.1 through Article 2.8 of 
the Code”. (The World Anti-Doping Code 2009, WADA, 2009b). In relation to 
these  rules,  WADA  can  consider  whether  that  any  tested  athlete  is  clean  or 
doped, guilty or not guilty, and/or a cheater or a champion. “The World Anti-
Doping Code was first adopted in 2003 and became effective in 2004. The 
enclosed  incorporates  revisions  to the  World  Anti-Doping  Code  that  were 
approved by the World Anti-Doping Agency Foundation Board on November 
17, 2007. The revised World Anti-Doping Code is effective as of January 1, 
2009” (The World Anti-Doping Code 2009, WADA, 2009b). 
 
1.2. Blood Doping Definition and Reasons 
 
Blood  doping  is  the  application  of  methods  and  use  of  substances  for  non-
medical reasons by healthy athletes to enhance oxygen (O2) delivery to tissues to 
increase  their  maximal  aerobic  power  leading  to  improved  aerobic  athletic 
performance  (Gaudard  et  al.,  2003;    Lippi  et  al.,  2006;    Elliott,  2008).  The 
artificial  manipulation  of  the  endurance  performance  enhancement  either  by 
using a prohibited substance or by the use of any prohibited method to enhance 
O2 transport to skeletal muscles and is therefore considered “doping” and when 
directly related to the blood content and parameters is specifically called “blood 
doping”.  In  addition,  injecting  the  hormone  erythropoietin  (EPO),  which  is  a  
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prohibited substance, and EPO gene manipulation are considered “blood doping” 
(The 2009 Prohibited List International standards, WADA, 2009a). The Injection 
of artificial blood substitutes, red blood cells (RBCs) or whole blood of any origin 
whether  by  autologous,  homologous  or  heterologous  transfusions,  which  are 
prohibited methods, are also considered “blood doping” (The World Anti-Doping 
Code  2009,  WADA,  2009b;    The  2009  Prohibited  List  International  standards, 
WADA, 2009a). 
 
The  aerobic  endurance  performance  can  be  assessed  by  the  delayed  time  to 
exhaustion and muscle fatigue and the increased maximum oxygen uptake (VO2 
max), defined as the highest rate at which O2 can be taken up and used by the 
body and skeletal muscle tissues during severe exercise (Gaudard et al., 2003). 
The increase in Hb concentration in blood, particularly in red blood cells (RBCs), 
and  the  manipulation  of  Hb-O2  affinity  and  release  (naturally  and  artificially 
induced  shifting  of  the  Hb-O2  dissociation  curve  to  the  right)  increase  the 
efficiency  of  O2  transport  and  delivery  to  peripheral  and  muscular  tissues, 
improves  and  increases  the  energy  production  leading  to  increased  muscular 
fatigue resistance and finally a better athletic performance (Lippi et al., 2006;  
Gaudard  et  al.,  2003;    Elliott,  2008).  The  latter  outcome  leaded  to  legal 
(healthy)  and  illegal  (doping)  practices  of  methods  and  substances  mainly  in 
endurance athletic competitions. 
 
1.3. Prohibited methods and substances used for Blood Doping and 
Enhancement of O2 delivery Capacity 
 
The increase in O2 delivery to skeletal muscle tissue can be manipulated and 
achieved by direct and indirect actions on Hb (Gaudard et al., 2003). See figure 
1.1 (Adopted from Gaudard et al., 2003, Lippi et al., 2006 Pascual et al., 2004 
and Elliott, 2008). 
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Figure 1.1 Prohibited Methods and Substances of Blood Doping (Adopted from Gaudard et al., 
2003, Lippi et al., 2006, Pascual et al., 2004 and Elliott, 2008). 
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1.3.1. O2 Delivery Enhancement by increasing Hb Mass and Concentration in 
Blood 
 
1.3.1.1. Blood Transfusions  
 
The infusion of whole blood or packed RBCs into human body intravenously is 
called  “blood  transfusion”  and  can  be  classified  into  3  different  categories 
according to the source of donation: heterologous, homologous and autologous 
transfusions. As mentioned earlier, all of these methods are prohibited to be 
used  by  athletes  according  to  WADA’s  rules  and  regulations  (The  World  anti-
doping code, WADA, 2009b;  The 2009 Prohibited List International standards, 
WADA, 2009a). 
 
Heterologous transfusions are transfusions of a specie’s blood to another specie; 
animal’s blood (e.g. calf and turtle’s blood) into human body or vice versa for 
clinical  and  research  reasons  and  to  human  and  animal  athletes  in  sports 
(Parisotto, 2006). Homologous blood transfusion is the infusion of whole or part 
of blood from the same specie but not from the same person; i.e. the transfusion 
of another person’s blood (Parisotto, 2006). On the other hand, autologous blood 
transfusion is the infusion of whole or part of a person’s own blood (Parisotto, 
2006) whereas the blood donor is the same as the transfusion recipient (Lippi et 
al., 2006). The basic use of blood transfusions is to save and enhance the life of 
patients  suffering  critically  from  acute  and  chronic  anaemia  and  because 
patients will not usually require the whole blood contents, the whole blood can 
be separated into components with the advanced biotechnology and the infusion 
of that component would be according to the patient’s specific diagnosis and 
prognosis  (Lippi  et  al.,  2006).  Autologous  blood  transfusion  starts  with  the 
withdrawal of 1 to 4 blood units, in which 1 blood unit consists of 450 ml of 
whole blood or 225 ml of concentrated RBCs, several weeks prior to competitive 
events (Lippi and Banfi, 2006) followed by the reinfusion of the stored blood 
units  several  days  prior  to  any  competitive  event  (Ashenden,  2002).  The 
withdrawn amount of blood is immediately replaced by the infusion of isotonic 
saline solution, then the blood is centrifuged and RBCs are separated and stored 
as  units  either  by  refrigeration  at  +4°C  or  frozen  at  -80°C  and  finally  these  
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stored  RBC  units  are  heated  to  +41°C  prior  to  reinfusion  (Morkeberg  et  al., 
2009a). 
 
Blood transfusions can elevate individual’s Hb concentration above normal that 
consequently  increases  VO2  max  (Ekblom,  2000).  This  explains  the  success  of 
USA’s cycling team in the 1984 Los Angeles Olympic  Games with the obvious 
abuse of blood  transfusions (Shaskey and Green, 2000). The reinfusion of 1350 
ml of autologous blood in six elite cross-country skiers were compared to control 
group of seven subjects resulted in an increase of Hb by 7.9% from before the 
phlebotomy  sample  and  14%  before  the  reinfusion  sample  (Berglund  et  al., 
1987). In a follow up study, The autologous transfusion of 1350 ml of 6 well 
trained cross country skiers resulted in improvements in race performance times 
after 3 hours and 14 days of reinfusion (Berglund and Hemmingson, 1987). The 
reinfusion of 1350 ml of freezer stored autologous blood in 12 well trained male 
and female former endurance athletes, phlebotomised 3 to 4 months prior to 
reinfusion, resulted in increased Hb concentrations significantly (Berglund et al., 
1989).  
 
Blood transfusions are not risk free methods of doping and can be fatal although 
it can lead to increases up to 20% of Hb and Hct (Lippi et al., 2006). Hct is the 
percentage of blood made up by RBCs (Parisotto, 2006) and sometimes called 
packed  cell  volume  or  erythrocyte  volume  fraction  (Thirup,  2003).  The  main 
complication of blood transfusions is the hyperviscosity syndrome characterised 
by  the  elevated  blood  thickness  and  viscosity,  lowered  cardiac  output, 
decreased blood flow velocity that eventually results in reduced O2 delivery to 
peripheral  tissues  (Lippi  et  al.,  2006).  Transfused  homologous  blood  induces 
reactions  like:  urticaria,  fever  and  anaphylactic  shock,  blood  born  infections 
like:  HIV,  syphilis,  hepatitis,  cytomegalovirus,  malaria  and  Creutzfeldt-Jakob 
disease (Lippi and Banfi, 2006). Autologous transfusion is safer, more convenient 
and maybe cheaper from homologous transfusion (Corrigan, 2002). 
 
1.3.2. Stimulation of Endogenous EPO and Erythropoiesis  
 
Erythropoietin (EPO) is a glycoprotein hormone, which is mainly produced and 
secreted by the by the kidneys (Jacobson et al., 1957) and maybe up to 10% is  
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made in the liver (Fried, 1972;  Fisher, 1979). EPO stimulates the proliferation 
and  differentiation  of  erythroid  progenitor  cells  in  the  red  bone  marrow  to 
develop into erythrocytes and then released into the blood stream (Gaudard et 
al., 2003). The newly released erythrocytes are immature RBCs containing nuclei 
and called reticulocytes (Retics) that contain residues of nucleic acid RNA (Banfi, 
2008).  Retics  have  a  larger  volume  than  RBCs  with  identical  Hb  content  but 
lower Hb concentration (D’Onofrio et al., 1995). RBCs have an average lifespan 
of 120 days however Retics are present and stay in the circulating blood for a 
period of 1-4 days until they loose their nuclei and full maturation to RBCs is 
achieved (Zucker-Franklin and Grossi, 2003). 
 
1.3.2.1. Altitude Training and Simulated Altitude Exposures 
 
High  altitude  causes  tissue  hypoxia  and  organisms  respond  and  adapt  to  this 
condition  by  erythropoiesis  (Samaja,  2001).  Hypoxia  causes  transcriptional 
activation of various genes for the encoding of glycolytic enzymes and growth 
factors and peptides, like EPO, which are regulated and controlled by hypoxia-
inducible factor 1 compound (HIF-1) that is responsible for the regulation and 
transcription of genes with hypoxia regulatory element (Gaudard et al., 2003;  
Mounier et al., 2006;  Mounier et al., 2009). The term “adaptation” refers to the 
physiological  adjustments  and  modification  that  took  place  over  generations 
under  stable  and  continuous  exposure  to  high  altitude  whereas  the  term 
“acclimatisation” describes the physiological changes of short exposures to high 
altitude (Lippi et al., 2006). According to Bartsch and Saltin (Bartsch and Saltin, 
2008) the elevation and ascending above sea level (ASL) are classified into the 
following: sea level - 500m ASL as a “near sea level”, 500m – 2000m ASL as a 
“low altitude”, 2000m – 3000m ASL as a “moderate altitude”, 3000m – 5000m 
ASL  as  a  “high  altitude”  and  any  altitude  above  5500m  ASL  as  an  “extreme 
altitude”. 
 
Altitude  and  hypoxic  training  can  be  classified  into  3  approaches  in  which 
athletes live and train at high altitude, live at low altitude but train at high 
altitude, live at high altitude and train at low altitude (Wilber, 2007). In 1991, 
levine et al. designed the first study to be conducted with the concept of “living 
high  and  training  low”  (Levine  et  al.,  1991)  and  was  shown  to  be  the  most  
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effective approach to improve athletic sea level endurance performance (Levine 
and Stray-Gundersen, 2001). Altitude and hypoxic training can be achieved by 
the elevation to natural terrestrial altitudes, simulated by hypoxic devices or 
mixture  of  both  natural  and  simulated  high  and  low  altitudes  (Wilber,  2001;  
Wilber, 2007;  Bartsch and Saltin, 2008). Simulated hypoxia and normoxia can be 
acquired by nitrogen dilution, supplemental O2, intermittent hypoxic exposures, 
hypoxic  apartments  and  sleeping  devices  such  as  Colorado  Altitude  Training 
Hatch
® and Hypoxico Tent System
® (Wilber, 2001). The brief exposure to hypoxia 
of 1.5-2.0 hours using theses devices hypothetically sufficient to stimulate RBCs 
synthesis (Wilber, 2001). 
 
Acclimatisation of four weeks at high altitude in conjunction with high intensity 
training  at  low  altitude  was  shown  to  sufficiently  enhance  the  athletic 
performance at sea level in female and male endurance elite athletes (Stray-
Gundersen  et  al.,  2001).  Twenty  four  days  of  living  high  at  2500m  ASL  and 
training low at 1000m and 1800m ASL resulted in increased erythropoiesis (serum 
EPO, transferrin, sTfr, Retics, Hb mass and RBC volume), increased VO2 max and 
improved 5000m performance times in elite male and female endurance skiers 
(Wehrlin et al., 2006). Living at simulated altitude of 2650m ASL and training at 
600m ASL for 5 days was sufficient to increase serum EPO levels significantly but 
did  not  increase  Retics  production  in  6  elite  male  runners  (Ashenden  et  al., 
2000). Altitude acclimatisation and training effects on athletic performance has 
been  shown  in  a  study  to  have  interindividual  variability  described  by 
“responders” and “non-responders” to altitude training although the plasma EPO 
concentration and RBC volume was significantly raised in all subjects but the 
significant  improvements  in  VO2  max  and  endurance  performance  were  only 
observed  in  the  “responders”  (Levine  and  Stray-Gundersen,  1997).  These 
findings where confirmed in a follow up study of living high and training low 
concept that there are individual variations in athletes responding to altitude 
training (Chapman et al., 1998). HIF-1, which controls the expression of EPO 
gene  upon  exposure  to  hypoxia,  can  not  be  used  to  identify  the  individual 
variations among “responders” and “non-responders” to live high and train low 
concept (Mounier et al., 2006). Numerous studies recruiting athletes for altitude 
and  hypoxic  training  have  shown  significant  increases  in  serum  EPO 
concentrations without improving performance, VO2 max or any erythropoietic  
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responses  of  increasing  Hct,  RBC  volume,  Hb,  Retics  or  soluble  transferrin 
receptor (sTfr) (Ashenden et al., 2000;  Julian et al., 2004;  Robach et al., 2006;  
Abellan et al., 2007;  Calbet et al., 2002;  Ventura et al., 2003;  Dehnert et al., 
2002;  Abellan et al., 2005). 
 
Training  at  high  altitude  or  in  hypoxic  environments  reduces  athletes’ 
performance  speed,  power  output  and  VO2  max  (Levine,  2002).  The 
acclimatisation  to  high  altitudes  leads  to  suppression  of  appetite,  protein 
synthesis inhibition, mild muscle atrophy and compensatory metabolic responses 
(Levine and Stray-Gundersen, 2001). With further elevation to higher altitudes, 
other complications can appear like: mountain sickness (headache, nausea and 
anorexia),  increased  pulmonary  ventilation,  elevated  heart  rate,  decreased 
plasma volume, decreased stroke volume and at very high altitudes pulmonary 
and cerebral oedema and sometimes coma (Bartsch and Saltin, 2008). 
 
Altitude training and artificially simulated altitude environments are less risky 
than other ways of blood doping which are currently considered unethical (Lippi 
et  al.,  2006),  debatable  (Wilber,  2001;    Wilber,  2007),  illegal  methods  to 
enhance endurance sports performance at sea level for their ability to reproduce 
most physiological and adverse effects of rHuEPO abuse (Ashenden et al., 2001), 
legal (Ashenden et al., 2004) but not prohibited by WADA (The 2009 Prohibited 
List International standards, WADA, 2009a). 
 
1.3.2.2. Gene Therapy (EPO Gene Doping) 
 
According to WADA, “The transfer of cells or genetic elements or the use of 
cells, genetic elements or pharmacological agents to modulating expression 
of endogenous genes having the capacity to enhance athletic performance, 
is prohibited” and considered “gene doping” and therefore when being applied 
to EPO gene then it is indirect EPO doping (The 2009 Prohibited List International 
standards  WADA,  2009a).  With  the  development  of  gene  transfer  technology, 
EPO  gene  might  be  targeted  as  well  as  other  genes  to  improve  athletic 
performance.  EPO  gene  doping  and  manipulation  mimics  the  effects  of 
exogenous EPO injections without the need for repeated doses (Unal and Unal, 
2004;  Diamanti-Kandarakis et al., 2005;  McCrory, 2003). EPO gene is one of the  
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primary  identified  genes  targeted  for  doping  (Azzazy  et  al.,  2005;    Azzazy, 
2010).  
 
One  of  the  possible  approaches  to  transfer  and  activate  EPO  gene  is  by 
combining and associating EPO gene with a carrying vector by the intramuscular 
injection  of  an  adenovirus  containing  EPO  gene  (Svensson  et  al.,  1997).  The 
intramuscular  injection  of  adeno-associated  virus  vectors  in  animals  can 
systemically deliver and produce supra-physiologic  levels of EPO (Bohl et al., 
2000;  Walker et al., 2005). The excessive and uncontrolled secretion of EPO 
leads  to  elevated  Hct  levels  that  increase  blood  viscosity  with  higher  risk  of 
thrombosis,  heart  attack,  liver  failure,  paralysis,  and  unexpected  deaths 
(McCrory,  2003;    Diamanti-Kandarakis  et  al.,  2005).  Experimental  EPO  gene 
therapy on baboons resulted in sharp raise in RBCs levels from 40% to 75% that 
leaded the  researchers  to  have  the  baboons’  blood  regularly  diluted  to  keep 
them alive (Zhou et al., 1998). 
 
The only possible way to detect EPO gene doping is by invasive procedures using 
molecular methods to recognise and indentify EPO transgenes or gene transfer 
vectors  that  is  logistically  inappropriate  to  screen  large  numbers  of  athletes 
(Diamanti-Kandarakis et al., 2005). Haematological passports (Malcovati et al., 
2003) and year round screening of athletes can help in detecting such abuse as 
athletes have alterations in haematological indices and reference ranges within 
and  between  seasons  (Unal  and  Unal,  2004).  The  indirect  haematological 
methods (Gore et al., 2003;  Sharpe et al., 2006) and the direct EPO urine test 
(Lasne, 2001;  Lasne et al., 2007) can be used as a screening tools for suspects 
and  athletes  who  test  positive  followed  by  direct  confirmatory  molecular 
analysis for EPO gene doping (Diamanti-Kandarakis et al., 2005). 
 
1.3.3. Exogenous EPO, Analogues and Mimetics  
 
In mid 1980s, human erythropoietin gene was cloned (Lee-Huang, 1984) and by 
mid  1990s  EPO  has  become  the  drug  of  choice  among  endurance  athletes  to 
improve  their  aerobic  competitive  performance  (Cazzola,  2002).  Technically, 
EPO  doping  has  several  advantages  compared  to  blood  transfusions  like:  the 
availability of blood donors, withdrawals, storage and reinfusion and delay in  
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training and decay in performance after blood withdrawal (Lippi et al., 2006). 
The abuse of EPO in international competitions as an ergogenic aid has been 
accentuated  by  a  number  of  disgraces  and  dishonours  with  approximately 
assessed use by 3% to 7% of elite professional endurance athletes (Wilber, 2002). 
EPO  improves  muscle  oxygenation  by  increasing  the  circulating  RBCs  via 
promoting,  differentiating  and  proliferating  the  erythroid  progenitor  cells 
(Pascual et al., 2004). EPO abuse for doping purposes have been supported by 
clinical  evidence  for  its  erythropoietic  and  ergogenic  benefits  owing  the 
significant enhancements of Hb, Hct, VO2 max, and increases in the duration of 
exercise endurance time (Wilber, 2002). Different biologically active isoforms of 
recombinant  human  EPO  (rHuEPO)  have  been  developed  and  were  named 
“Epoetin”s for the preparations that have an amino acid sequence similar to the 
naturally occurring endogenous EPO with the addition of the Greek letters α, β, 
ω and δ as suffixes to distinguish among the chemical composition and/or the 
nature  of  the  added  carbohydrate  moieties  (Pascual  et  al.,  2004).  Clinically, 
rHuEPO  have  been  and  being  used  primarily  to  treat  and  correct  anaemia 
associated with chronic kidney failure in patients undergoing renal dialysis and 
secondary anaemia  progressed  by  AIDS,  cancer,  hepatitis  C  infection,  chronic 
infections, heart failure, autoimmune diseases, transplantation of bone marrow 
and other seriously ill pre- and postoperative patients (Bunn, 2007;  Lamon et 
al., 2010).  
 
After the development of recombinant DNA techniques and the expression of 
human  EPO  gene,  Epoetin  α  (Epogen
®,  Epoade
®)  and  Epoetin  β  (Epoch
®, 
Eritrogen
®) are produced and isolated from Chinese hamster ovary (CHO) cell 
lines with minor structural differences but similar physiological effects (Pascual 
et al., 2004;  Diamanti-Kandarakis et al., 2005). Epoetin β has probably slight 
pharmacokinetic  advantages,  over  Epoetin  α,  for  instance  a  longer  terminal 
elimination half-life for its increased molecular weight and the decrease in the 
amount of sialylated glycan remnants (Storring et al., 1998;  Deicher and Hörl, 
2004). Epoetin ω (Epomax
®and Hemax
® ) is a sialoglycoprotein obtained from 
baby  hamster  kidney  (BHK)  cells  and  differs  from  Epoetin  α  and  β  by  its 
physiochemical  properties  with  similar  pharmacological  effects  (Diamanti-
Kandarakis et al., 2005). Epoetin ω being more biologically active than Epoetin 
α,  but  this  was  concluded  by  small-scale  clinical  studies  (Deicher  and  Hörl,  
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2004). Epoetin δ (Dynepo
®) or Gene-Activated EPO (GA-EPO) is produced by gene 
activation in human firbrosarcoma cell lines, which are engineered to induce the 
human endogenous EPO gene by transfecting its DNA (Diamanti-Kandarakis et 
al., 2005;  Barbone et al., 1999). The pattern of glycosylation and the sequence 
of amino acids of endogenous EPO will possibly vary from the ones for Epoetin δ 
because it is not produced by renal cells (Diamanti-Kandarakis et al., 2005). 
 
The need for less frequent doses of exogenous EPO directed the search towards 
the structural characteristics of endogenous EPO and the in vivo potency of EPO 
that  leaded  to  the  discovery  and  development  of  the  Novel  Erythropoiesis-
Stimulating Protein (NESP), also known as Darbepoietin α (Aranesp
®) (Diamanti-
Kandarakis  et  al.,  2005;    Lamon  et  al.,  2010;    Elliott,  2008).  NESP  is  a 
glycoprotein hormone containing 5 N-liked carbohydrate chains instead of 3 that 
makes it different from endogenous EPO and other rHuEPO’s by 5 amino acids 
substitutions resulting in the addition of 2 N-linked oligosaccharide attachment 
sites and leading to weaker binding to EPO receptor and extended serum half-
life  (Elliott,  2008;    Lamon  et  al.,  2010;    Diamanti-Kandarakis  et  al.,  2005). 
Continuous  erythropoietin  receptor  activator  (CERA)  is  an  erythropoiesis-
stimulating protein that can be administered at less frequent dosage of once 
every  three  to  four  weeks  (Macdougall,  2005).  The  main  criteria  of  CERA’s 
mechanism  of  action  is  the  weaker  binding  to  EPO  receptors  and  even  more 
rapid  dissociation  from  these  receptors  that  increases  its  plasma  half-life 
(Macdougall, 2005). The painful routs of administration of rHuEPO intravenously 
and  subcutaneously  leaded  research  to  develop  a  more  suitable  way  for  the 
simplicity,  ease  and  convenience  of  use  by  oral  EPO  analogues  (Diamanti-
Kandarakis  et  al.,  2005).  EPO  mimetics,  which  are  substitutes  of  EPO,  are 
synthetic  molecules  with  the  capability  to  dimerise  EPO  receptors  and  act 
similarly as EPO and rHuEPO (Pascual et al., 2004). Hematide
  ® is a synthetic 
dimeric and EPO mimetic peptide that activates EPO receptors, increases and 
prolongs EPO serum half-life without producing anti-EPO antibodies (Diamanti-
Kandarakis  et  al.,  2005;    Elliott,  2008).  Encapsulated  rHuEPO  in  genetically 
engineered  cells  with  semi-permeable  membrane  polymers  prevents  antigen 
identification and immune system rejection by isolating the encapsulated cells 
that  enhanced  erythropoiesis  in  healthy  subjects  (Regulier  et  al.,  1998). 
Encapsulated rHuEPO in dipalmitoylphosphatidylcholine (DPPC) liposomes made  
 
28 
up of soybean-derived sterylgluciside (SG-liposomes) and soybean-derived sterols 
(SS-liposomes)  were  administered  in  rats  and  compared  to  subcutaneous 
injections  and  the  results  showed  a  maintenance  of  EPO  activity  by  the 
liposomes that reduced the aggregation of EPO molecules with higher retention 
of SG-liposome encapsulated rHuEPO activity than SS-liposomes (Qi et al., 1995). 
 
The pharmacokinetics, following subcutaneous rHuEPO administration, appear to 
be linear for dosages from 50 to 1000 IU.kg
-1 but not for a lower dosage of 10 
IU.kg
-1 with mean half-life for a 50 IU.kg
-1 dose repeated daily of about 3.5 hours 
and total clearance, about three times higher in athletes, of 17 ml.h
-1.kg
-1 for 
athletes and 6.5 ml.h
-1.kg
-1 for untrained subjects (Varlet-Marie et al., 2003a;  
Varlet-Marie  et  al.,  2003b).  The  half  life  is  five  times  shorter  following 
intravenous administration (Varlet-Marie et al., 2003b). A delayed increase of Hb 
(up to 9.6%) ,Hct (up to 8.3%), EPO in serum, macrocytes, Retics, and sTfr levels 
is noticed after rHuEPO administration (Parisotto et al., 2000a;  Connes et al., 
2003).  Following  the  initial  administration,  these  markers  (Parisotto  et  al., 
2000a) increase significantly from the third to the tenth day and at all the times 
continually  followed  by  a  negative  temporary  feedback  of  EPO  synthesised 
endogenously which can be interpreted and considered as an indirect marker of 
rHuEPO administration (Varlet-Marie et al., 2003a) Epoetin δ has mean plasma 
half-life  of  7-12  hours  when  injected  intravenously  and  18-20  hours  of 
subcutaneous administration (Deicher and Hörl, 2004). Darbepoietin-α has mean 
half-life of approximately two to three times longer than it is for rHuEPO; 25.3 
hours  when  administered  intravenously  and  48.8  for  the  subcutaneous 
administration  route  (Macdougall  et  al.,  1999).  Darbepoietin-α  has  a  longer 
terminal elimination half-life than Epoetin α and β ranging from 6.8-8.5 up to 
25.3 hours when administered intravenously and 19.4-24.2 up to 48.8 hours once 
administered  subcutaneously  (Macdougall  et  al.,  1999).  After  less  frequent 
dosages,  darbepoietin-α  showed  to  have  an  increased  residence  time  with 
equivalent  pharmacodynamic  effects,  of  elevating  Hb  levels,  compared  to 
Epoetin α (Macdougall et al., 1999). The required dosage of Darbepoietin-α do 
not differ between the subcutaneous injection and intravenous administration 
with less frequent administration compared to other Epoetins (Macdougall et al., 
1999). CERA has extended plasma half-life estimated and reported to be seven 
times longer when compared to other standard rHuEPOs with maintained Hb and  
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Retics values for 12 weeks at a dose of 5-8 µg (Macdougall, 2005). At this dose, 
CERA could increase Retics by 262% and Hb from 16-23 g.L
-1 with over 50% of 
anaemic patients having Hb ≥20 g.L
-1. CERA has mean elimination half-life of 133 
to 137 hours for both subcutaneous and intravenous administrations (Macdougall, 
2005).  
 
Athletes misusing erythropoiesis-stimulating proteins and agents may put their 
cardiovascular  system  at  great  risk  (Lippi  et  al.,  2006;    Elliott,  2008).  With 
evidence based positive effects of rHuEPO therapy on physical performance, side 
effects  and  risks  arose  including  hypertension,  thrombosis,  of  the  vascular 
access,  and  hyperviscosity,  dehydration,  thrombosis,  hypertension  and  severe 
headache (Raine, 1988;  Eagleton and Littlewood, 2003;  Elliott, 2008;  Sikole et 
al., 2002).The long term rHuEPO therapy in patients can cause pure red cell 
aplasia, and the development of anti-EPO antibodies (Casadevall et al., 2002;  
Eagleton and Littlewood, 2003;  Casadevall, 2003). RBC aplasia is a condition 
characterised by an arrest in RBCs production which is rare but life-threatening 
condition (Deicher and Hörl, 2004;  Eagleton and Littlewood, 2003;  Casadevall, 
2003;  Casadevall et al., 2002).  
 
1.3.4.  O2  Delivery  Enhancement  by  Using  Artificial  O2  Carriers  (Blood 
Substitutes) 
 
According to WADA, any method ” Artificially enhancing the uptake, transport 
or  delivery  of  oxygen,  including  but  not  limited  to  perfluorochemicals, 
efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-
based  blood  substitutes,  microencapsulated  haemoglobin  products)”  is 
considered a doping method (The 2009 Prohibited List International standards, 
WADA, 2009a). Artificial O2 carriers or blood substitutes are synthetically made 
solutions and bioengineered to be capable of binding, transporting and unloading 
O2 molecules from the lungs to body tissues as RBCs does (Farrar and Grocott, 
2003). Currently, almost all artificial O2 carriers are in advanced clinical trails 
(Kim and Greenburg, 2004;  Henkel-Honke and Oleck, 2007). As an alternative to 
EPO Doping and blood transfusions, these solutions may possibly be used in the 
sports fields.  
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The main idea of manufacturing blood substitutes is to replace the O2 delivery 
function  of  RBCs  by  overcoming  and  avoiding  the  logistical  problems  and 
disadvantages of whole blood transfusions including: storage, refrigeration, cost, 
immunological reactions, blood group and type matching, blood born diseases 
and infections, and the immediate supply of large blood quantities in severe 
blood loss cases of trauma, anemia and tissue ischemia (Kim and Greenburg, 
2004;  Henkel-Honke and Oleck, 2007;  Corrigan, 2002;  Lowe, 2003). 
 
1.3.4.1. Exogenous and Synthetic Allosteric Modifiers of Hb 
 
Some drugs where developed to modify the allosteric properties of Hb and work 
in synergy with 2,3-diphosphoglycerate (2,3-DPG), the native allosteric effector 
of Hb. Among these drugs, the analogous of clofibrate, bezofibrate and indanyl 
derivative  known  as  RSR-13,  RSR-4  and  RSR-46,  respectively  being  the  most 
potent and prompt modulators to decrease the affinity of Hb to O2 and release 
of it to hypoxic tissues (Kunert et al., 1996;  Hou et al., 2004;  Phelps Grella et 
al.,  2000).  Pharmacologically,  bezofibrate  and  clofibrate  derivatives  (RSR 
derivatives) are the most potent synthetic allosteric Hb modifier agents (Safo et 
al., 2001;  Phelps Grella et al., 2000;  Eaton et al., 2007;  Papassotiriou et al., 
1998;  Abraham et al., 1992) with RSR-13 being on the top lead of the clinical 
trials. The primary goal of manufacturing these drugs was after the need for 
tissue oxygenation and increasing O2 tension in tumor tissues with hypoxic cells 
to increase the sensitivity and response of cancer patients to radiotherapy (Hou 
et al., 2004;  Safo et al., 2001).  
 
When RSR-13 binds to RBCs membrane, without damaging the cell membrane, it 
decreases the affinity of Hb to O2 and thus more release of O2 molecules to 
tissues by shifting the O2-Hb dissociation curve to the right (Phelps Grella et al., 
2000;  Eaton et al., 2007;  Papassotiriou et al., 1998). RSR-13 interacts with Hb 
leading to raised peripheral tissues oxygenation that can be indicated to treat 
tissue ischemia, hypoxia and in cases of blood loss caused by trauma, bleeding 
and various types of anaemia (Safo et al., 2001). RSR-13 is in phase III clinical 
trials with current failure to comply with drug safety and initial goal of clinical 
indication, use and manufacture (Safo et al., 2001;  Elliott, 2008). As a possible 
ergogenic  aid  and  Doping  agent,  RSR-13  should  be  used  at  the  day  of  
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competition. With traces up to 24 hours of last administration, RSR-13 has a 
short  half-life  of  4  to  5  hours  with  easy  delectability  in  urine  by  gas 
chromatography/mass spectrometry (Breidbach and Catlin, 2001). 
 
1.3.4.2. Perfluorocarbon Based Emulsions (PFCs) 
 
Perfluorochemicals (PFCs) are highly fluorinated hydrocarbons with the ability to 
dissolve and carry blood gases, especially O2 and CO2, to various body tissues 
(Henkel-Honke and Oleck, 2007;  Lowe, 2003) rather than binding to theses gases 
as native Hb does (Gaudard et al., 2003). PFCs have hydrophobic nature and 
therefore  they  were  made  into  emulsions  to  dissolve  blood  gases  (Kim  and 
Greenburg, 2004). The emulsified liquid form of PFCs can be safely introduced in 
the body as a temporary solution for tissue ischemia (Lowe, 2003). Based on and 
following Henry’s law, PFCs’ ability to carry and deliver O2 is in equilibrium with 
O2 partial pressure (pO2) (Spiess, 2009). Thus, PFCs can act as prompt O2 carrier 
only at high blood O2 concentration. At low pO2, the linear relationship between 
PFCs  and  blood  O2  concentration  compromises  the  O2  dissolving  and  delivery 
ability  of  PFCs  which  makes  native  Hb,  which  has  a  sigmoidal  O2  binding 
relationship with O2, a better tissue-oxygenating agent (Elliott, 2008). 
 
Fluosol-DA  was  the  first  O2  carrier  drug  to  be  developed  as  Perfluorocarbon 
emulsion in 1980’s (Kerins, 1994). The first generation PFCs have a 3 to 4 hours 
half-life in the blood circulation and are cleared from the body within 7 days 
exhaled  air  (Flaim,  1994).  The  second  generation  PFCs  were  made  in  better 
injectable form and in smaller emulsion particles for better tissue oxygenation 
(Spiess, 2009;  Lowe, 2003). Oxygent, a second generation PFC, has a longer 
half-life of up to 9 hours in the blood circulation and a total clearance from the 
body within 4 days (Spahn et al., 1999;  Spahn, 1999). 
 
To be used as sports doping agent, PFCs administration should be accompanied 
with continuous highly concentrated O2 supplementation that is impractical and 
incompatible in the official sports fields and events (Lippi et al., 2006;  Eichner, 
2007;  Elliott, 2008). Owing the fact that PFCs are not metabolized by the body 
and  eliminated  mainly  by  the  lungs  (Lippi  et  al.,  2006;    Elliott,  2008),  the 
detection method is simply by measuring PFCs concentration of the exhaled air  
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using  thermal  vapor  analyser  (Shaffer  et  al.,  1997)  or  by  infrared  absorption 
method (Mazzoni et al., 1999). 
 
1.3.4.3. Haemoglobin Based O2 Carriers (HBOCs) 
 
Haemoglobin  Based  O2  Carries  (HBOCs)  are  cell  free  haemoglobin  molecules 
which are obtained from bovine blood, human blood, or recombinant human DNA 
by  genetic  engineering  (Corrigan,  2002).  As  blood  substitutes,  HBOCs  were 
developed to replace O2 delivery functions of RBCs and decrease the need for 
donated blood supplies in cases of trauma and during surgeries (Chang, 2000), 
ischemic  vascular  and  life  threatening  advanced  conditions  (Weiskopf,  2010). 
Native Hb is a tetramer consisting of four subunits: two α-subunits and two β-
subunits (Varlet-Marie et al., 2004). Infused cell free Hb dissociates into smaller 
α and β dimmers with short intravascular half-life and increased renal clearance 
and nephrotoxicity (Standl, 2001). In addition, cell free Hb has high O2 affinity 
cause by the decresed contact with phosphates that leads to shifting the O2–
dissociation  curve  to  the  left  (Chen  et  al.,  2009).  Consequently,  biochemical 
modification  of  cell  free  Hb  is  essentially  required  to  overcome  the  above 
mentioned complications to act as efficient blood substitute. These techniques 
started and developed with intermolecular and intramolecular cross-linking of 
Hb  tetramers,  conjugation  with  macromolecules,  polymerisation  and 
encapsulation of Hb tetramers in liposomes, microencapsulation in lipid vesicles 
and finally progressed to nanoencapsulation of Hb tetramers in biodegradable 
polymers (Chen et al., 2009;  Gaudard et al., 2003;  Standl, 2001;  Chang, 2003).  
 
PolyHeme, HemAssist and Hemopure (HBOC-201) are examples of HBOC drugs 
that  have  progressed  and  advanced  to  phase  II  and  III  clinical  trials  with  no 
current approval in Europe and USA for clinical use (Weiskopf, 2010;  Chen et 
al.,  2009).  In  addition  to  renal  toxicity,  the  main  complication  of  former 
generations  of  HBOCs,  nitric  oxide  scavenging  by  modern  HBOCs  is  the  main 
complication leading to the oxidation of free Hb, systemic vasoconstriction and 
vascular hypertension that compromise the function of HBOC drugs to deliver O2 
to deprived body tissues (Irwin et al., 2008;  Chang, 2003;  Chen et al., 2009;  
Weiskopf, 2010;  Rooney et al., 1993). Despite the fact that all HBOC drugs carry 
O2 from the lungs and almost all HBOC drugs unload O2 to tissues with coherent  
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evidence of efficacy in different animal models, a less consistent proof of O2 
delivery efficacy has been demonstrated in clinical trials (Weiskopf, 2010). In a 
study on euvolumic animal subjects, HBOC derived from bovine RBCs decreased 
O2  delivery  to  tissues  during  normoxia  and  hypoxia  and  failed  to  act  as  an 
artificial O2 carrier (Irwin et al., 2008).  
 
For anti-doping testing purposes, HBOCs can be easily and directly detected in 
blood. The presence of HBOCs in blood is very visible for the discolouration of 
separated plasma or serum to deep red compared to HBOCs free plasma and 
serum  (Gaudard  et  al.,  2003).  HBOC  drugs  can  also  be  detected  by 
electrophoresis screening technique (Lasne et al., 2004) and by chromatographic 
profiling (Varlet-Marie et al., 2004). 
 
1.4. Detection of Blood Doping (Transfusions and EPO)  
 
Homologous  blood  transfusion  is  easier  to  detect  from  autologous  reinfusion 
because exogenous RBCs’ antigens differ from donor to recipient blood and these 
antigens  can  be  easily  expressed  and  discriminated  (Ashenden,  2002).  Via 
pheynotyping  certain  RBC  antigens,  the  detection  of  homologous  blood 
transfusions  can be  achieved  by the  distinction of  antigens of the  donor and 
recipient RBCs by flow cytometry method using blood bank antisera combined 
with a fluorescent-labeled additional antibody focused in opposition to human 
immunoglobulin  (Nelson  et  al.,  2002;    Nelson  et  al.,  2003;    Lippi  and  Banfi, 
2006). A method was proposed to detect the autologous transfusions in cross-
country skiers using the combinations of blood parameters of Hb, bilirubin, iron 
and serum EPO of autologous reinfusion of refrigerator-stored blood but resulted 
in false negatives of 50% (3 athletes) of the blood-doped group (Berglund et al., 
1987). The same method was applied to endurance athletes during the first four 
weeks of reinfused thawed freezer-stored blood (RBCs) with no robust evidence 
of blood doping using autologous blood transfusions (Berglund et al., 1989). To 
date,  there  is  no  standard  and  practical  method  to  detect  autologous  whole 
blood or RBCs transfusions (Lippi and Banfi, 2006;  Morkeberg et al., 2009a).  
 
r-HuEPO  abuse  detection  is  always  difficult  for  its  short  half-life  and  the 
variability  in  interindividual  drug  compounds’  pharmacokinetics  of  the  
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intravenous  and  subcutaneous  routes  (Gaudard  et  al.,  2003;    Diamanti-
Kandarakis et al., 2005;  Lamon et al., 2010;  Wilber, 2002). Several published 
methods were developed to detect rHuEPO abuse directly (Wide et al., 1995;  
Lasne,  2001;    Lasne  and  de  Ceaurriz,  2000;    Lasne  et  al.,  2007)  indirectly 
(Wilber,  2002)  and  indirectly  using  multiparametric  models  (Parisotto  et  al., 
2000a;  Parisotto et al., 2001) but only two methods, which are by Parisotto et 
al, 2000a and in combination with lasne and de Ceaurriz, 2000 and lanse, 2001, 
were adopted by IOC at the Sydney Olympic Games 2000 and the Salt Lake City 
Winter Olympic Games 2002 (Lamon et al., 2010). To prevent bacterial activity 
in urine, a stability test was added by WADA for all urine samples obtained for r-
HuEPO screening (Lamon et al., 2010). Epoetin α , β, ω and NESP (darbepoietin-
α)  are  all  detectable  using  the  same  methods  whereas  GA-EPO  or  Epoetin  δ 
(Dynepo
®)  could  probably  be  very  difficult  to  detect  by  the  direct  method 
because of its similar structure to endogenous human EPO (Diamanti-Kandarakis 
et al., 2005).  
 
1.5. Development of EPO and Blood Doping Statistical Models and 
Equations  
 
Endurance competitions and events like cycling, cross-country skiing and long 
distance running are the games in which “blood doping” is used and preferred. 
Endurance athletes are usually tested for their serum and urine EPO levels. It 
was easier to detect the totally synthetic EPO but that was only possible in the 
old synthetic version where it leaves traces in blood and urine. Physiologically, 
EPO  is  released  by  the  kidneys  and  the  pharmaceutical  EPO  is  made  and 
designed for renal failure patients who undergo renal dialysis. EPO is usually lost 
after renal dialysis and that was the medical urge to manufacture, improve and 
imitate the naturally occurring human EPO. Recently, with new technology and 
developed  pharmaceutical  sciences  and  techniques,  a  new  version  of  the 
hormone EPO have been released as r-HuEPO, as mentioned earlier (Parisotto et 
al., 2000a;  Lippi et al., 2006;  Gaudard et al., 2003). The tests which were 
developed to detect EPO abuse were unable to distinguish between the injected 
exogenous EPO and the endogenously produced EPO (Parisotto et al., 2000a). 
Therefore, some other blood parameters like red blood cells count (pack cell 
volume) or Hct and Hb concentration have been considered by some federations  
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(Parisotto et al., 2000a), like the International Cycling Union (UCI) in the late 
20
th century for anti-doping purposes and medical reasons after the causalities of 
some doped athletes who ended up dying in the competition and sports fields 
(Eichner,  1992;    Shaskey  and  Green,  2000;    UCI,  2009).  Later  on,  other 
parameters and blood contents have been considered to help in the detection of 
EPO and blood doping. Recticulocytes (immature red blood cells) Haematocrit 
(RetHct) and sTfr concentration, in addition to Hct and Hb have been used and 
applied  in  certain  models  and  equations  according  to  their  normal  existing 
values and were compared to values that most athletes posses (Parisotto et al., 
2001;  Parisotto et al., 2000a;  Parisotto et al., 2000b). Parisotto et al. 2000 and 
2001  designed  equations  that  include and  relate  these  blood  parameters  and 
their values according to the time of EPO doping method and course, i.e. during 
and  after  the cessation of  the  doping  procedure.  These equations  have been 
called the ON-model and OFF-model equations and are almost specific to EPO 
doping rather than other ways of blood doping. In Sydney 2000 Olympic Games 
and up to date, the ON-model in combination with the positive urine EPO sample 
(e.g. Lasne and de Ceaurriz, 2000) were agreed on by the IOC and later on by 
WADA  and  some  federations  like  the  International  Associations  of  Athletics 
Federations (IAAF). That was the most important and first step in the detection 
of  blood  doping  and  the  application  of  blood  sample  testing.  IOC  medical 
committee used to depend on and trust urine tests alone and that is why they 
did not agree on the blood test alone and excluded the OFF-model outcomes. 
The ON-model outcome combined with urine EPO concentration (traces) results 
were  very  weak  tools,  at  that  time  when  these  models  and  urine  detection 
methods  were  developed,  to  detect  all  EPO  doped  athletes  because  most  r-
HuEPO traces in serum and urine are cleared out from body systems between 24 
to 72 hours (Bressolle et al., 1997;  Souillard et al., 1996). 
 
Following 2000 Olympic Games, there was an urgent need to modify and develop 
more  models  and  equations.  The  first  generation  of  ON-  and  OFF-models 
(Parisotto  et  al.,  2000a)  were  insensitive  and  unspecific  in  relation  to  the 
percentage of false positives. Most elite long distance runners are born, raised, 
lived  and  trained  in  high  altitude  geographic  areas  but  they  also  descend  to 
compete on sea level fields. These athletes already have high blood parameters 
values and consequently higher ON- and OFF-model scores compared to other  
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athletes who originate from low altitudes (at or close to seal level). It was also 
found that an adjustments and alterations of these athletes’ blood parameters 
and profiles when they change their altitude, as a compensatory homeostatic 
responses  (Moore  et  al.,  2007).  Second  generation  ON-  and  OFF-models  have 
been developed by Gore et al. to overcome these false positives and minimise 
them by 1 in 1,000 incidence (Gore et al., 2003). These new models have been 
developed  in  accordance  to  the  time  of  season,  venue,  and  altitude  of  the 
collected sample. WADA’s policy is to track and obtain urine and blood samples 
of competing registered athletes in all conditions, i.e. out of completion (while 
training or resting in at home), pre-competition and in-competition. The third 
generation  model  was  developed  by  Sharpe  et  al.  that  can  monitor  athletes 
hematological profiles in a longitudinal way (Sharpe et al., 2006). These third 
generation  equations  are  based  on  the  OFF-hr  scores  (from  the  second 
generation developed by Gore et al., 2003) and Hb concentration values of the 
same  athlete  of  the  same  and  previous  seasons  (Sharpe  et  al.,  2006).  Some 
federations  like:  the  International  Ski  Federation  (FIS)(FIS,  2009),  UCI  (UCI, 
2009) and IAAF (IAAF, 2009;  Ojiambo et al., 2008), in cooperation with WADA 
and  anti-doping  researchers’  suggestions,  started  to  process,  develop  and 
formulate  what is  so  called  “Athletes  Haematological  Passports”  proposed  by 
Malcovati et al. (Malcovati et al., 2003) and blood profiles of skiers (Morkeberg 
et  al.,  2009b),  cyclists  (Morkeberg  et  al.,  2009c)  and  endurance  runners 
(Ojiambo et al., 2008). These passports will include all athletes’ information, all 
collected samples data of all conditions until the accreditation of the current 
OFF-models  (Gore  et  al.,  2003),  and  the  techniques  of  sample  collection 
procedures as the direct detection methods of “blood doping”. 
 
1.6. Haematological Passports 
 
With the development of the third generation model (Sharpe et al., 2006) and 
haematological  passports  for  any  given  endurance  athletes  (Malcovati  et  al., 
2003),  it  is  the  only  possible  way  to  find  out  and  detect  blood  doping  using 
rHuEPO and autologous blood transfusions in regards to anti-doping rules stated 
by WADA for abnormal haematological high values of non pathological reasons. 
Athletes of endurance sports especially in IAAF, UCI and FIS should provide at 
least  four  blood  samples  a  year,  pre-competition,  and  inform  their  closest  
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National  Anti-Doping  Organization  (NADO)  of  their  whereabouts  (Hanstad  and 
Loland, 2009). 
 
1.7. Masking Substances and Methods 
 
After achieving the desired Hct and Hb concentrations, blood doped athletes 
usually use blood thinners, anticoagulants, anti-hypertensive drugs and plasma 
volume expanders. Aspirin, heparin, beta blockers, normal saline and increasing 
the  fluid  intake  before,  during  and  after  the  event  and  just  before  sample 
collection,  which  are  the  usually  used  procedures  to  prevent  any  medical 
complications and mortalities while competing and as masking methods to dilute 
the blood sample. 
 
According  to  WADA  any  masking  method  or  substance  that  mask  a  doping 
substance  physically  and  or  chemically  by  tampering,  intravenous  infusions 
and/or oral intake to dilute the urine or blood sample including but not limited 
to:“Diuretics,  probenecid,  plasma  expanders  (e.g.  intravenous 
administration of albumin, dextran, hydroxyethyl starch and mannitol) and 
other substances with similar biological effect(s)” ; violates the world anti-
doping  code  and  considered  doping  (The  2009  Prohibited  List  International 
standards,  WADA,  2009a).  Glycerol  has  been  recently  added  to  the  2010 
prohibited substances list just after the completion of the experiments of this 
thesis and the publication of Easton et al., manuscript (The 2010 Prohibited List 
International standards, WADA, 2010;  Easton et al., 2009). 
 
1.8. Hyperhydration and Blood Dilution as a Masking Method  
 
The reason for prohibiting the use of plasma expanders is for their direct dilution 
effect on plasma and therefore a diluted blood (haemodilution) sample which 
lower the doping substances concentrations in blood, below the threshold, that 
can be considered as coherent evidence to accuse, ban and apply sanctions and 
punishments to athletes who are doped (figure 1.2.). Hct% and Hb concentration 
are used to calculate plasma volume indirectly (Dill and Costill, 1974). Proper 
hydration by euhydration (Fudge et al., 2008) and hyperhydration (Zorbas et al.,  
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1995) may help endurance athletes to perform better in endurance events in 
contrast  to  hypohydration  (Sawka  et  al.,  1992a;    Sawka  et  al.,  1992b)  and 
dehydration  (Cheuvront  and  Haymes,  2001)  especially  when  exercising  and 
competing in environments with elevated temperatures. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Indirect Athletes’ Blood Sample Manipulation. (Masking Substances and Methods). 
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1.9. Glycerol(Gly) and Creatine(Cr) as masking substances  
 
Glycerol(Gly) supplementation may be considered as an ergogenic aid by means 
of  hyperhydration  (Nelson  and  Robergs,  2007;    Robergs  and  Griffin,  1998). 
Supplementation  with  Creatine  (Cr)  induces  ergogenic  effects  directly  on  the 
anaerobic  pathway  of  energy  supply  (Greenhaff  et  al.,  1994;    Kilduff  et  al., 
2002;  Kilduff et al., 2003). However, Cr supplementation also attenuates the 
effect of heat on exercise (Kilduff et al., 2004;  Hadjicharalambous et al., 2008;  
Easton et al., 2007) by means of hyperhydration too.  
 
The combination of Cr/Gly supplementation showed synergistic effects by means 
of hyperhydration that improved exercise performance in heat (Easton et al., 
2007)  and  with  different  postures  (Easton  et  al.,  2009)  that  attenuated 
orthostatic intolerance too; when these studies showed significant increases in 
total body water (TBW) and plasma volume that were calculated using Hct and 
Hb (Dill and Costill, 1974). Specifically, Gly increased extracellular water (ECW) 
and Cr increased intra cellular water (ICW) (Easton et al., 2007;  Easton et al., 
2009). 
 
1.9.1. Creatine (Cr) 
 
Creatine (Cr) or creatine monohydrate has been used at supra-physiological level 
doses worldwide not only by professional elite athletes but also by recretionl 
sports individuals seeking improved physical performance (Bemben and Lamont, 
2005)  in  both  supra-maximal  short  term  as  well  as  sub-maximal  prolonged 
exercise and competitions in different climatic situations. In the early 1830s, 
Chevreul discovered Cr and by 1847 Liebeg confirmed and theorised that Cr is an 
existing article in meat and in some way associated with muscle performance 
but the scientific investigation for Cr extraction and processing from meat for 
oral consumption did not start until the beginning of 1900s (Bemben and Lamont, 
2005). By the 1970’s, some eastern European countries started to use Cr as an 
ergogenic aid for athletic performance; and by early 1990s, scientific studies in 
UK  and  USA  started  to  focus  extensively  on  Cr  supplementation  on  potential 
performance (Silber, 1999). Cr has been proven scientifically and legally to date 
in the enhancements of high to even maximal intensity exercise performance in  
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sports requiring single, multiple or repetitive bouts like weight lifting, spiriting, 
football and similar sports (Casey and Greenhaff, 2000). However, the focus in 
the  following  paragraphs  and  chapters  will  be  mainly  on  the  hyperhydration 
capabilities of Cr supplementation on haemodilution rather than the ergogenic 
effects.  Brief  introduction  of  biochemical  reactions,  physiological  responses, 
effects and side effects of Cr can better help in the understanding of how Cr 
loading  for  7  days  at  a  dose  of  approximately  20  g.day
-1  can  produce  such 
hyperhydration results and maybe plasma expansion and haemodilution effects. 
 
Cr is a nonessential naturally occurring dietary compound that can be ingested 
exogenously by eating meat or fish and can also be synthesised endogenously in 
human  body  mainly  by  the  liver  (Bemben  and  Lamont,  2005).  Cr  is  known 
biochemically  as  methylguanidine-acetic  acid  and  made  up  of  3  amino  acids 
glycine,  arginine  and  methionine  (Casey  and  Greenhaff,  2000;    Bemben  and 
Lamont,  2005).  At  first,  glycine  and  arginine  are  joined  to  produce 
guanidinoacetate and after that S-adenosylmethionine adds a methyl group for 
the  production  of  Cr  (Bemben  and  Lamont,  2005).  After  the  synthesis  of  Cr 
mainly in the liver, it is released into the blood stream and then transported into 
the muscle fibers and sarcoplasm by active transport which is facilitated by a 
sodium-dependent transporter known as Cr transporter-1 (Demant and Rhodes, 
1999;  Terjung et al., 2000). The skeletal muscle tissue is considered the main 
host that contains almost all the Cr ingested and synthesised in human body in 
which approximately 60% is phosphorylated and known as phosphocreatine (PCr) 
with the remaining 40% in free form (Bemben and Lamont, 2005). An average 
human body of 70 kg person generally posses 120-140 g of Cr in the skeletal 
muscle tissues and about 2 g.day
-1 of this pool is lost and excreted in the urine as 
creatinine that is restored by the endogenous synthesis of about 1 g.day
-1 and 
further exogenous 1 g.day
-1 from oral ingestion of normal balanced diet of mixed 
food (Bemben and Lamont, 2005). As a dietary supplement, Cr ingestion as an 
ergogenic  aid  can  operate  through  different  but  related  mechanisms  on  the 
skeletal muscle tissue (Bemben and Lamont, 2005). Once intracellular PCr levels 
are  raised  by  the  uptake  of  Cr  into  muscle  fibers,  it  facilitate  the  rapid 
rephosphorylation  of  ADP  molecules  back  to  ATP  via  the  action  of  Cr  kinase 
during short duration high intensity exercise and particularly if that exercise is 
repeated and separated by short rest intervals (Casey et al., 1996a;  Demant and  
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Rhodes, 1999;  Mesa et al., 2002). Cr availability into sarcoplasm and myofibrils 
facilitates  the  high-energy  phosphate  molecules  movement  between  myosin 
heads  (thick  filaments)  and  mitochondria  and  enhances  the  sarcoplasmic 
reticulum to uptake Calcium ions that lead to better occupying the heads of the 
thick filaments in crossbridge binding and cycling and in sustaining the tension 
during muscular contraction (Bemben and Lamont, 2005;  Demant and Rhodes, 
1999;  Mesa et al., 2002;  Casey et al., 1996b;  Leemputte et al., 1999;  Hespel 
et  al.,  2002;    Wyss  and  Kaddurah-Daouk,  2000).  As  PCr  levels  decline  with 
exercise and ADP levels start to rise, it can stimulate the glycolysis rate-limiting 
enzyme,  known  as  phosphfructokinase,  to  rapidly  raise  the  process  of 
rephosphorylation  of  ADP  to  ATP  (Bemben  and  Lamont,  2005;    Demant  and 
Rhodes, 1999;  Mesa et al., 2002). However, this rephosphorylation process is 
further enhanced and accelerated by the presence of free and phosphorylated Cr 
within  the  muscular  tissue  in  improving  the  intracellular  homeostasis  via 
stimulating Cr kinase reactions by acting as a pH buffer in raising the acidosis 
and making the most of using hydrogen ions (Mesa et al., 2002;  Demant and 
Rhodes, 1999;  Bemben and Lamont, 2005). Cr supplementation has been found 
to decrease the concentrations of the accumulated plasma ammonia (Birch et 
al., 1994) and hypoxanthine (Balsom et al., 1993) during muscular metabolism in 
sustaining  the  rephosphorylation  process  of  ADP  to  ATP  during  high  intensity 
exercise despite the amplified work and torque produced by the skeletal muscle 
contractions (Casey et al., 1996a;  Casey and Greenhaff, 2000). Skeletal muscle 
hypertrophy and elevated protein synthesis rate can be linked to elevated PCn 
levels that are induced by Cr ingestion and high intensity exercise (Bemben and 
Lamont, 2005;  Casey et al., 1996a;  Casey et al., 1996b;  Casey and Greenhaff, 
2000). Universally, it appears that there is an agreement in the literature that 
free Cr and PCr are higher in fast twitch type II glycolytic skeletal muscle fibers 
compared  to  slow  twitch  type  I  aerobic  skeletal  muscle  fibers  with  modest 
scientific evidence that support the differences in PCr levels between males and 
females (Mesa et al., 2002;  Pastoris et al., 2000;  Casey et al., 1996a;  Casey et 
al., 1996b).  
 
As a result of the loading effect of Cr (from 5-7 days), protein synthesis in the 
skeletal muscle tissue can be stimulated and protein catabolism can be inhibited 
by  the  osmotic  gradient  that  moves  the  water  from  the  extracellular  
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compartment  into  the  intracellular  compartment  of  the  skeletal  muscle  cells 
(Haussinger et al., 1993). This increased ICW has an effect on increasing body 
mass  in  most  subjects  whereas  some  authors  consider  it  controversial 
(Poortmans and Francaux, 2000;  Kilduff et al., 2002;  Kilduff et al., 2003). 
 
The use of Cr supplementation by athletes maybe not safe on the long run and 
certain precautions should be followed to avoid the few adverse effects that 
have  been  cited  as  to  the  precise  timing  and  the  preparation  of  fluid 
supplements  containing  Cr  (Bemben  and  Lamont,  2005).  To  prevent  the 
degradation of Cr to creatinine, Cr should be dissolved in warm water or fluid 
mixture and the solution should be made fresh prior to oral consumption (Easton 
et  al.,  2007;    Kilduff  et  al.,  2003).  Cr  should  be  well  dissolved  in  the 
supplementation fluid before ingestion to prevent gastrointestinal distress and 
stomach upset (Mesa et al., 2002). Gastrointestinal distress can occur from Cr 
consumption  during  or  immediately  following  exercise  (Vanderberie  et  al., 
1998). However, no gastrointestinal distress was reported in a study by Kilduff et 
al. when Cr was supplemented immediately after exercise (Kilduff et al., 2003). 
Cr supplementation does not affect or impair the liver or kidneys physiological 
function but caution should considered in individuals and athletes with any pre-
existing conditions and associated pathologies of the renal or hepatic functions 
especially with long-term use (Bemben and Lamont, 2005). Muscle cramps are 
sometimes  experienced  with  Cr  supplementation  after  exercise  but  this  is 
possibly related to the high intensity of the exercise (Terjung et al., 2000;  Mesa 
et  al.,  2002)  or  may  be  due  to  intramuscular  electrolyte  imbalance  and 
dehydration (Bemben and Lamont, 2005). No muscle cramps have been reported 
with Cr supplementation with high intensity workout when the subjects were 
adequately hydrated and hyperhydrated (Kilduff et al., 2003).  
 
1.9.2. Glycerol (Gly) 
 
Glycerol(Gly)  has  been  recently  considered  a  banned  substance  (The  2010 
Prohibited List International standards, WADA, 2010). Gly (1,2,3- propanetriol) is 
the metabolite of a 3-carbon alcohol which is naturally synthesised in the human 
body, found in and between all body cells at low concentrations of less than 0.1 
mmol.L
-1 (Robergs and Griffin, 1998) and known to be the main structure that  
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makes up a triglyceride molecule (Frank et al., 1981). Gly can be formed from 
the action of glycerol kinase on glycerol-3-phosphate (Robergs and Griffin, 1998) 
and by the de-esterification of a triglyceride molecule found in specific blood 
vessels, the adipose tissue, the liver and the skeletal muscle tissue (Frank et al., 
1981).  The  synthesis,  catabolism  and  metabolism  of  Gly  are  mediated 
particularly by the enzymes glycerol kinase and glycerol dehydrogenase which 
are tissue target specific and mostly found in the kidneys and the liver (Bortz et 
al., 1972) with smaller concentrations found in the intestinal mucosa (Frank et 
al.,  1981)  and  skeletal  muscle  tissues  (Newsholme  and  Taylor,  1969).  The 
conversion and turnover of Gly to a glycolytic substrate occurs for consequent 
metabolism which are principally controlled by the renal and hepatic function 
and  its  removal  from  the  blood  circulation  depends  on  the  activity  and 
abundance of the glycerol kinase and glycerol dehydrogenase enzymes in those 
specific body tissues (Robergs and Griffin, 1998). The metabolism of Gly occurs 
mainly (about 80%) in the liver with the remaining 10-20% metabolised in the 
kidneys  depending  on  the  action  of  the  enzyme  glycerol  kinase  and  its 
availability (Frank et al., 1981;  Nelson and Robergs, 2007). After the conversion 
of Gly into glycerol-3-phosphate, two pathways are possible for the metabolism 
of Gly (Frank et al., 1981;  Nelson and Robergs, 2007). The oxidation of glycerol-
3-phosphate, accounts for about 70-90% of Gly metabolic process (Frank et al., 
1981;  Nelson and Robergs, 2007), produces dihydroxyacetone phosphate by the 
action of glycerol-3-phosphate dehydrogenase enzyme that leads to either the 
production of glucose and 2 pyruvate molecules via gluconeogenesis (Frank et 
al., 1981;  Berg et al., 2007) or pyruvate and 2 ATP molecules during glycolysis 
(Stryer, 1995; Berg et al., 2007). The second pathway of glycerol-3-phosphate 
metabolism, accounts for about 10-30 % of Gly metabolic process (Frank et al., 
1981;  Nelson and Robergs, 2007). This process occurs when two free fatty acid 
molecules are added to glycerol-3-phosphate to produce phosphatidate which 
transforms into triglyceride when an extra (third)  free fatty acid molecule is 
added  (Robergs  and  Roberts,  1997;    Berg  et  al.,  2007;    Robergs  and  Griffin, 
1998). The concentration of serum Gly at rest is approximately 0.05 mmol.L
-1 
and can be elevated to about 0.3 mmol.L
-1 by the effect of increased lipolysis 
related to caloric restriction or drawn out exercise (Robergs and Griffin, 1998). 
Acting as a substrate, Gly is used and thought to be an ergogenic aid especially 
in sports requiring endurance performance. In addition, the slow rate by which  
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Gly is metabolically cleared from the blood circulation plays an essential role in 
the  persistent  hydrating  qualities  of  this  compound  and  in  the  process  of 
hyperhydration as well (Nelson and Robergs, 2007).  
 
The  use  of Gly  by  the  oral  and  intravenous  routes  have  been researched  for 
about 60 years and clinically between the years 1961 and 1980 to treat cerebral 
oedema,  intracranial  hypertension,  intraocular  hypertension  (known  as 
glaucoma),  postural  syncope  and  to  enhance  rehydration  especially  in 
gastrointestinal disorders (Robergs and Griffin, 1998). Gly hyperhydration with 
the addition of fluids intake have been used since 1987 for the aim of increasing 
and  elevating  total  body  water  (TBW)  by  about  700  ml  for  the  purpose  of 
improving thermoregulation and performance of endurance exercise especially in 
hot environments (Robergs and Griffin, 1998). The use of Gly with exercise as an 
ergogenic  supplement  for  better  thermoregulatory  responses  through 
hyperhydration  and  fluid  retention  have  been  tested  and  showed  decreased 
thirst  sensation  and  dehydration  (Wingo  et  al.,  2004)  and  decreased  rectal 
temperature (Easton et al., 2007;  Lyons et al., 1990), heart rate, and rate of 
perceived exertion (RPE) (Easton et al., 2007). In contrast, some other authors 
showed no significant improvements in athletic performance (Magal et al., 2003;  
Marino et al., 2003).  
 
The infusion and ingestion of Gly at a dose of more than 1.0 g.kg 
-1 body mass 
leads to increases in serum Gly concentration to about 20 mmol.L
-1  that elevate 
serum osmolality to more than 10 mOsmol.kg 
-1 (Robergs and Griffin, 1998). Gly 
induces  osmotic  gradient  between  cells  and  tissues  (Berne  and  Levy,  1998) 
because of its even distribution and availability in all body fluid compartments 
except for the aqueous humour and cerebrospinal fluid (Lin, 1977) that causes 
intracranial and intraocular dehydration especially when infused intravenously 
with  the  possibility  of  body  hyperhydration  when  ingested  orally  at  doses 
starting with 1.0 g.kg 
-1 body mass (Nelson and Robergs, 2007). Because of the 
characteristic properties of the blood brain barrier, Gly has this discriminative 
permeability (Nelson and Robergs, 2007). When taken orally, passive diffusion is 
the mechanism through which Gly gets absorbed by the gastrointestinal tract 
(Lin, 1977). Gly acts as a solute for its hyperosmotic chemical properties and 
when it is absorbed it leads to raises in the concentration of the solute in all  
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fluid compartments rather than outside them that causes an osmotic gradient 
directing the fluids to move from the area of lower osmotic concentration to the 
area  that  posses  higher  osmotic  concentration  (i.e  Gly)  to  create  osmotic 
equilibrium outside and with in all fluid compartments; leading to the even body 
fluids distribution (water) in the ECW and ICW water compartments (Nelson and 
Robergs, 2007;  Berne and Levy, 1998). However, when this distribution is not 
created and higher concentrations of Gly is found in the ECW compartment, the 
fluids  are  forced  to  move  to  the  ECW  compartment  following  that  osmotic 
gradient and causing intracellular dehydration and increases in the blood volume 
possibly by about 2.5% for an average 70 kg human with blood volume of 5 L; 
that if Gly hyperhydration raised TBW of about 1 L (1000 ml) casing a raise in 
blood volume of about 125 ml (Guyton, 1991;  Nelson and Robergs, 2007). Gly 
ingestion were shown to be more effective on increasing ECW rather than ICW 
(Easton et al., 2007). 
 
1.10. Posture and time as masking methods 
 
Plasma  volume  and  some  blood  parameters  change  with  postural  changes 
(Maughan  et  al.,  1994)  especially  with  exercise  (Greenleaf  et  al.,  1979c;  
Greenleaf et al., 1979b;  Greenleaf et al., 1979a;  Gonzalez-Alonso et al., 1999). 
During the process of the development of EPO and blood doping indirect models, 
the  supine  resting  postural  position  was  chosen  and  standardised  with  time 
ranging between 5 to 10 min to minimise the confounding effects of posture on 
blood parameters and plasma (Parisotto et al., 2000a;  Parisotto et al., 2001;  
Ashenden et al., 2001;  Sharpe et al., 2002;  Ashenden et al., 2003). The time 
course, training and altitude has their effects on plasma, blood parameters and 
on  EPO  detection  models  (Sharpe  et  al.,  2002).  However,  WADA  had 
standardised the blood collection posture and this is the posture followed by 
WADA’s authorised blood collection personnel that in the Guidelines for Blood 
Collection; article 5.7.5 “In order to ensure the same conditions for all, the 
Athlete  shall  remain  seated  and  relaxed  for  at  least  10  minutes  before 
undergoing Venipuncture” (WADA Standards and Harmonization Guidelines for 
Blood Collection, WADA, 2008). The time of blood and urine sample collection 
following exercise is very crucial and may change the validation of the sample. 
Recently, false positive result of NESP (darbepoietin-α) was detected in urine  
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sample  collected  following  exercise  whereas  negative  result  of  NESP 
(darbepoietin-α) in urine of a sample obtained from the same subject an hour 
after exercise session (Beullens et al., 2006). 
 
1.11. Hypothesis and Aim of the Experiments 
Athletes  that  use  a  number  of  illicit  substances  and  methods  such  as  blood 
transfusions, erythropoiesis stimulating agents and blood substitutes could resort 
to using masking substances and methods to overcome detection when tested by 
WADA  personnel.  Hyperhydration  has  the  potential,  therefore,  to  act  as  a 
masking agent. Postural changes can also have a direct effect on plasma volume 
and therefore could influence the outcome of doping tests. There is therefore an 
urgent need to examine the effects of novel hyperhydration techniques alone 
and in combination with postural changes on blood profiles and therefore on the 
potential to influence the result of doping tests. A series of experiments were 
designed  and  presented  in  this  thesis  to  assess  the  effects  of  a  novel 
hyperhydration  strategy  involving  Cr  and  Gly  supplementation  (aimed  at 
elevating TBW via effects on ICW and ECW) on blood parameters (e.g. Hct and 
Hb  values).  The  effects  of  posture  on  these  blood  parameters  were  also 
assessed.   
 
The aims of the experiments described in this thesis were to examine: 
i)  the effects of hyperhydration using Cr/Gly supplementation on blood 
parameters (Hb and Hct) in the supine posture.  
ii)  the effects of postural changes in euhydrated subjects moving from 
supine, sitting to sanding posture.  
iii)  the effects of hyperhydration using Cr/Gly supplementation (Cr for 7 
days  and  Gly  on  the  7
th  day  only)  on  blood  parameters  (Hb,  Hct, 
%Retics, and OFF-hr model) when adopting a standard sitting posture 
(WADA’s standard position). 
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2. Methods 
 
2.1. Creatine and Glycerol Hyperhydration Experiment Methods 
(EXP1) 
 
2.1.1. Subjects 
 
Eight  healthy  male  subjects  (six  Europeans  and  two  Middle  Easterns),  were 
invited  to  participate  and  volunteer  in  this  study.  Prior  to  the  first 
familiarisation trial, subjects signed and gave their written informed consent to 
take  part  in  the  present  study  which  was  approved  by  the  Local  Ethics 
Committee  and  was  performed  according to  the  code  of ethics  of  the  World 
Medical  Association  (Declaration  of  Helsinki).  The  subjects  had  the  following 
characteristics (mean ± s.d.): age: 26 ± 6 years, height: 176 ± 7 cm, weight: 73.3 
± 7.6 kg. Subjects were interviewed to confirm that all subjects were Cr free for 
at least 8 weeks prior to the study. The investigators did not reveal prior to the 
interview that subjects would be excluded if they had supplemented with Cr in 
the  previous  8  weeks.  The  subjects  were  fully  informed  of  any  risks  and 
discomforts  associated  with  the  experiments  before  giving  their  written 
informed  consent  to  participate.  Discomforts  may  include  but  not  limited  to 
painful cannulation, blood withdrawal or magnitude of commitment required. All 
subjects were advised to revise their medical history with their local general 
practitioners.  
 
2.1.2. Experimental design  
 
Each subject was required to visit the laboratory on at least 3 occasions for 
measurement  and  analysis  of  urine,  blood  and  blood  content.  The  supine  0
o 
postural position was chosen to comply with previous studies (Parisotto et al., 
2001;  Sharpe et al., 2002;  Ashenden et al., 2003).  However, in this study, 
variability  in  Hb  and  Hct  were  the  main  focus  points  in  addition  to  urine 
osmolality.  The  first  (familiarisation)  and  second  (pre-supplementation) 
experimental trials were identical and conducted prior to any supplementation 
intervention  to  establish  baseline  values.  The  final  experimental  trial  (post- 
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supplementation) was conducted after supplementation with Cr and Gly for 7 
days. The supplementation regimen only commenced if physiological responses 
between baseline experimental trials differed by less than 5%; only one subject 
had  to  repeat  a  third  baseline  experimental  trial.  Cr/Gly  supplementation 
consisted of 11.4 g of Cr·H2O (Creatine 6000-ES, Iovate Health Sciences Research 
Inc., Canada) (equivalent to 10 g Cr) and Gly of 1.0 g.kg 
-1 body mass (Aldrich-
Chemical,  Milwaukee,  WO,  U.S.A),  flavoured  with  200  ml  of  commercially 
available, sugar-free, flavoured diluting juice made up in 1 L of warm water 
(approximately  50
oC).  The  solution  was  cooled  to  room  temperature  before 
being consumed twice daily (once in the afternoon and once in the evening) for 
6 days and once more 5 hours before the experimental exercise trial. 
 
Each supplement was made fresh prior to consumption in order to prevent any 
degradation of Cr to creatinine. This fluid-loading strategy has been shown to be 
the most effective in a comparison of several Cr/Gly supplementation regimens 
(Easton  et  al.,  2007;    Easton  et  al.,  2006).  Subjects  were  identified  and 
classified  as  “responders”  to  Cr  supplementation  if  the  results  showed  an 
increase  in  body  mass  by  0.2  Kg  (Easton et al.,  2007;    Kilduff  et  al.,  2003). 
Subjects were asked to maintain their normal diet and minimise caffeine intake 
to one cup of tea or coffee per day to lessen any possible effects of caffeine on 
normal diuresis (Neuhäuser-Berthold et al., 1997;  Riesenhuber et al., 2006) and 
possible confounding effects of caffeine on Cr (Vandenberghe et al., 1996). Five 
hours prior to the familiarisation and pre-supplementation trials subjects were 
required to ingest 1 L of water to match fluid ingestion volume with the post-
supplementation trial. On all of the experimental test days, subjects ingested 
further 500 ml of water 1 hour prior to the experimental trial in an attempt to 
ensure that all subjects were euhydrated (Convertino et al., 1996). 
 
2.1.3. Procedures 
 
Subjects  arrived  at  the  laboratory  on  the  day  of  each  experimental  trial 
following a 3 hour fast and having refrained from alcohol, caffeine and strenuous 
exercise the day before. Upon arrival at the laboratory, subjects were asked to 
provide a 20 ml sample of urine in order to assess hydration status (Shirreffs and 
Maughan, 1998). Body mass (Avery Berkel 33/448, W & T Ltd., U.K.) and height 
(Leicester  stadiometer,  Invicta  Plastics  Ltd,  U.K.)  were  measured  before  
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subjects were instructed to lay in supine (0
o) postural position on a plinth for 30 
min  with  both  arms  abducted  to  the  level  of  the  heart.  During  this  period, 
subjects  left  or  right  arms  were  prepared  to  be  cannulated  by  trained 
phlebotomist. Tourniquet was strapped on the right or left arm and particularly 
over the brachial artery (Parisotto et al., 2001;  Sharpe et al., 2002;  Ashenden 
et  al.,  2003).  A  20  G  indwelling  catheter  was  inserted  into  the  right  or  left 
anticubital  vein  by  butterfly  needle  cannula  (Biovalve,  Laboratories 
Pharmaceutics VYGON, France) and connected to multidirectional stopcock for 
infusion therapy and monitoring (Discofix-2, B/BRAUN, B.Braun Melsungen AG, 
Melsungen, Germany), stabilised with an adhesive non-abrasive tape and flushed 
with  2  ml  isotonic  saline  0.9%  Na/Cl  (0.9%w/v  Sodium  Chloride  Intravenous 
Infusion  BP,  Mini-Plasco  NaCl,  B/BRAUN,  B.Braun  Melsungen  AG,  Melsungen, 
Germany).  A  10  ml  blood  sample  was  collected  every  10  min.  The  venous 
cannula  was  kept  patent  by  a  10  ml  infusion  of  the  isotonic  saline  between 
samples. Body water compartments were estimated using a Bodystat Multiscan 
5000 Bioimpedance analyser (Bodystat Ltd, Isle of Man, U.K.) after 15 min of the 
supine position rest. This method allows TBW and ECW to be estimated; from 
these measurements ICW can also be deduced. There is good evidence to suggest 
that the estimation of TBW by bioimpedance is reliable and valid when subjects 
are euhydrated (O’Brien et al., 2002). To date, several studies have successfully 
utilised this technique in order to estimate hyperhydration induced changes in 
TBW (Easton et al., 2007;  Kilduff et al., 2004). Subjects were advised to remain 
as  stable  as  possible  for  the  whole  experiment  time  and  especially  before 
obtaining  blood  samples  and  measurement  of  body  water  compartments.  All 
experimental trials were conducted strictly at sea level barometric pressure with 
an ambient temperature maintained at 23 ± 0.5
oC.  
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Table 2.1. Experimental Design (EXP1) 
 
 
 
 
 
 
 
 
 
 
Table 2.2. Experimental procedures (EXP1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test  Week   Supplementation 
Familiarisation  Week 1  No supplements 
Pre-Supplementation  Week 2  No supplements 
Pre-Supplementation  
( if difference more than 5%) 
 
Week 3  No supplements 
Post-Supplementation  Week 3 or 4  Cr + Gly for 7 days 
Time 
 
Posture 
-15 
min 
0 
min 
5 
min 
10 
min  
15 
min 
20 
min 
25 
min  
30 
min 
 
Supine 
( 0˚) 
Urine 
Sample 
and 
Cannulation 
No 
Blood 
No 
Blood 
First  
10 ml 
Blood 
Sample 
Body water 
(bioimpedence)  
Second 
10 ml 
Blood 
Sample 
No 
Blood 
Third  
10 ml 
Blood 
Sample  
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2.2. Postural Changes Experiment Methods (EXP2) 
 
2.2.1. Subjects  
 
Ten  healthy  subjects  (two  Europeans,  four  Middle  Eastrens,  one  Asian,  one 
African and two South Americans), were invited to participate and volunteer in 
this  study.  Prior  to  this  one  trail  test  study,  subjects  signed  and  gave  their 
written informed consent to take part in the present study which was approved 
by  the  Local  Ethics  Committee  and  was  performed  according  to  the  code  of 
ethics of the World Medical Association (Declaration of Helsinki). The subjects 
had the following characteristics (mean ± s.d.): age: 27 ± 3 years, height: 170 ± 
6  cm,  weight:  76.3  ±  8.7  kg.  Subjects  were  interviewed  to  confirm  that  all 
subjects were free from consuming substances and supplements that may retain 
water or having any diuretic effects. The subjects were fully informed of any 
risks and discomforts associated with the experiment before giving their written 
informed  consent  to  participate.  Discomforts  may  include  but  not  limited  to 
painful  cannulation,  blood  withdrawal  or  length  of  the  experiment  time 
especially in standing position. All subjects were advised to revise their medical 
history with their local general practitioners.  
 
2.2.3. Experimental design 
 
Each  subject  was  required  to  visit  the  laboratory  on  only  one  occasion  for 
measurement and analysis of blood content. The supine (0
o) postural position 
was chosen to conform to previous studies, i.e. from 5 min to maximum and not 
exceeding 10 min (Parisotto et al., 2001;  Sharpe et al., 2002;  Ashenden et al., 
2003).  The  sitting  postural  position  was  adopted  from  the  WADA’s  only 
authorised  posture  to  obtain  blood  samples  for  anti-doping  purposes  (WADA 
Standards  and  Harmonization  Guidelines  for  Blood  Collection  WADA,  2008). 
However, the standing postural position was used to compare and refer both 
supine and sitting postures. In this study, Hb and Hct fluctuations were the only 
focus points. Subjects were asked to maintain their normal diet and minimise 
caffeine intake to one cup of tea or coffee in the day of experiment to lessen 
any possible effects of caffeine on normal diuresis (Neuhäuser-Berthold et al., 
1997;    Riesenhuber  et  al.,  2006).  On  the  experimental  test  day,  subjects  
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ingested 500 ml of water 1 hour prior to the experimental trial in an attempt to 
ensure subjects were euhydrated (Convertino et al., 1996). 
 
2.2.4. Experimental Procedures 
 
Subjects arrived at the laboratory on the day of the experimental trial following 
a 3 hour fast and having refrained from alcohol and strenuous exercise the day 
before. Upon arrival at the laboratory, subjects were prepared to be cannulated 
by a trained phlebotomist. The cannulation process was performed exactly as in 
EXP1. Then, subjects were instructed to lay in a plinth in a supine (0
o) postural 
position. In this experimental phase subjects remained in the supine position for 
a further 30 min before being instructed to move into sitting postural position 
for 30 min and finally to standing postural position for 30 min as well. A 10 ml 
blood sample was collected every 10 min. The venous cannula was kept patent 
by a 10 ml infusion of isotonic saline between samples. Subjects were instructed 
to relax their muscles, especially their calf muscles, at all the postural phases. 
Tests were to be immediately terminated if subjects complained of dizziness or 
light-headedness at any time of the postural positions. In the standing postural 
position,  subjects  were  standing  against  a  wall  and  were  provided  with 
supporting  pillows  against  their  lumbar  spines  to  insure  that  they  are  as 
comfortable as possible. All experimental trials were conducted strictly at sea 
level barometric pressure and with an ambient temperature maintained at 23 ± 
0.5
oC.  
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Table 2.3. Experimental Design and Procedures (EXP2) 
 
 
 
 
 
 
 
 
 
 
 
 
Time 
           
Posture 
-15-0  
min 
5 
min 
10  
min 
15 
min 
20  
min 
25 
min  
30  
min 
Supine ( 0˚) 
 
Cannulation  None  10 ml 
blood 
None   10 ml 
blood. 
None  10 ml 
blood 
Sitting 
 
None  None  10 ml 
blood 
None   10 ml 
blood. 
None  10 ml 
blood 
Standing 
 
None  None  10 ml 
blood 
None   10 ml 
blood. 
None  10 ml 
blood  
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2.3. Running with Creatine and Glycerol Hyperhydration  
Experiment Methods (EXP3) 
 
2.3.1. Subjects 
 
Seven European healthy male athlete subjects, who trained at least 3 times a 
week and who at least competed once in national competitions, were invited to 
participate and volunteer in this study. Prior to the first familiarisation trail, 
subjects  signed  and  gave  their  written  informed  consent  to  take  part  in  the 
present  study  which  was  approved  by  the  Local  Ethics  Committee  and  was 
performed  according  to  the  code  of  ethics  of  the  World  Medical  Association 
(Declaration of Helsinki). The subjects had the following characteristics (mean ± 
s.d.): age: 22 ± 2.5 years, height: 176 ± 6 cm, weight: 71.4 ± 8.85 kg, BMI: 23 ± 
1.7 kg·(m
2)
-1 and VO2 max 58.4 ± 6 ml.kg
-1.min
-1. Subjects were interviewed to 
confirm that all subjects were Cr free for at least 8 weeks prior to the study. 
The investigators did not reveal prior to the interview that subjects would be 
excluded if they had supplemented with Cr in the previous 8 weeks. The subjects 
were fully informed of any risks and discomforts associated with the experiments 
before  giving  their  written  informed  consent  to  participate.  Discomforts  may 
include but not limited to painful cannulation, blood withdrawal or length of the 
experiment time. All subjects were advised to revise their medical history with 
their local general practitioner.  
 
2.3.2. Experimental design 
 
Each subject was required to visit the laboratory on at least 4 occasions for 
measurement  and  analysis  of  VO2  max,  urine,  blood  and  blood  content.  The 
sitting  postural  position  was  chosen  to  standardise  WADA’s  only  authorised 
posture  to  obtain  blood  samples  from  the  selected  athletes  prior  to  testing 
(WADA  Standards  and  Harmonization  Guidelines  for  Blood  Collection  WADA, 
2008). However, in this study, which also focuses on hyperhydration that might 
be a masking method in blood doping detection/ deterring purposes, Hb, Hct, 
reticulocytes (%Retics) and OFF-hr score fluctuations are the main focus points. 
The first trial was a VO2 max test. The second (familiarisation) and third (pre- 
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supplementation) experimental trials were identical and conducted prior to any 
supplementation  intervention  to  establish  baseline  values.  The  final 
experimental trial (post-supplementation) was conducted after supplementation 
with  Cr  for  7  days  and  Gly  for  one  day  only  (on  the  7
th  day).  The 
supplementation regimen and concentrations of Cr and Gly provided were the 
same as in EXP1. The solution was cooled to room temperature before being 
consumed twice daily (once in the afternoon and once in the evening) for 6 days 
and once more 5 hours before the experimental exercise trial; the latter was by 
the addition of Gly to the mixture. Each supplement was made fresh prior to 
consumption in order to prevent any degradation of Cr to creatinine. Subjects 
were  identified  and  classified  as  “responders”  to  Cr  supplementation  if  the 
results showed an increase in body mass by 0.2 Kg (Easton et al., 2007;  Kilduff 
et al., 2003). Subjects were asked to maintain their normal diet and minimise 
caffeine intake to one cup of tea or coffee per day to lessen any possible effects 
of caffeine on normal diuresis (Neuhäuser-Berthold et al., 1997;  Riesenhuber et 
al., 2006) and possible confounding effects of caffeine on Cr (Vandenberghe et 
al., 1996). Five hours prior to the familiarisation and pre-supplementation trials 
subjects were required to ingest 1 L of water to match fluid ingestion volume 
with  the  post-supplementation  trial.  On  each  of  the  experimental  test  days, 
subjects ingested 500 ml of water 1 hour prior to the experimental trial in an 
attempt to ensure subjects were euhydrated (Convertino et al., 1996).  
 
2.3.3. Procedures 
 
Subjects  arrived  at  the  laboratory  on  the  day  of  each  experimental  trial 
following a 3 hour fast and having refrained from alcohol, caffeine and strenuous 
exercise the day before. Upon arrival at the laboratory, subjects were asked 
change  into  preferred  comfortable  running  clothing  and  to  provide  a  20  ml 
sample of urine in order to assess their hydration status (Shirreffs and Maughan, 
1998).  Nude  Body  mass  (Avery  Berkel  33/448,  W  &  T  Ltd.,  U.K.)  and  height 
(Leicester  stadiometer,  Invicta  Plastics  Ltd,  U.K.)  were  measured  before 
subjects  were  instructed  to  be  in  sitting  postural  position  in  an  armed  chair 
comfortably for 10 min. During this period, subjects’ arms were prepared to be 
cannulated  by  trained  phlebotomist.  The  cannulation  process  was  performed 
exactly as in EXP1. No blood or urine samples were collected at the first test. All  
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10 ml blood samples were collected at room temperature (20-21°C) with the 
relative humidity of 30-40% after sitting for 10 min exactly. The venous cannula 
was kept patent by a 10 ml infusion of isotonic saline after the first, second and 
last samples. Subjects were advised to remain as stable as possible for the whole 
blood collection time i.e. 10 min. The first 10 ml blood sample was collected 
just before kindly moving subjects to the environmental (climate) chamber to 
start  the first 30 min running session at 10
oC (10.45 ± 0.23
oC ) with relative 
humidity of 70% (72.0 ± 1.1%) on a motorised treadmill (Woodway, Germany) at 
1% grade and on a speed set to 60% of their VO2 max. Then, the treadmill was 
stopped gradually and subjects were asked to step off the treadmill and were 
kindly removed out of the chamber. Subjects then asked to rest for 30 min. 
During this interval, subjects were asked to return back to sitting posture at 
room temperature for 10 min, without ingesting any sort of fluids, to obtain the 
second 10 ml blood sample. At the last 20 min of the resting period, nude body 
mass  was  obtained  in  order  to  assess  the  fluid  loss.  Subjects  were  asked  to 
replace the fluid loss by the given equivalent amount of water. After this resting 
period,  subjects  were  asked  to  move  back  to  the  environmental  (climate) 
chamber to start the second 30 min running session at 35
oC (34.72 ± 0.19°C) and 
with the relative humidity of 70% (71.5 ± 0.9%) on the treadmill at 1% grade and 
on  a  speed  set  to  60%  of  their  VO2  max.  Then,  the  treadmill  was  stopped 
gradually and subjects were kindly removed from the chamber to be seated for 
10  min  at  room  temperature  to  obtain  the  last  10  ml  blood  sample  without 
ingesting any sort of fluids. After obtaining the last blood sample, subjects were 
allowed to drink their preferred soft drinks, cool down on treadmill and offered 
water and showering facilities. All experimental trials were conducted strictly at 
sea level barometric pressure. 
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Table 2.4. Running with Creatine and Glycerol hyperhydration experimental design (EXP3) 
 
 
 
 
 
 
 
 
Table 2.5. Experimental Procedures (EXP3) 
 
 
 
 
 
 
 
 
 
Test  Week   Supplementation 
 VO2 max 
 
Week 1  No supplements 
Familiarisation 
 
Week 2  No supplements 
Pre-Supplementation  Week 3  No supplements 
Post-Supplementation  Week 4  Cr for 7 days + Gly on 7
th day 
 
Time 
(min) 
-15  -10 
 
0 ￿ ￿ ￿ ￿ 
30 
40 
 
50￿ ￿ ￿ ￿ 
70 
70￿ ￿ ￿ ￿ 
100 
120 
 
120 
￿ ￿ ￿ ￿∞ 
Test / 
procedure 
 
 
Urine 
Sample 
and 
Cannulation 
First 
10 ml 
Blood 
Sample 
Running 
30 min 
at 60% 
VO2 max 
(10ºC) 
Second 
10 ml 
Blood 
Sample 
 
Rest 
20 min 
+ 
Replace 
fluid 
loss by 
water 
Running 
30 min 
at 60% 
VO2 max 
(35ºC) 
Third 
10 ml 
Blood 
Sample 
 
Recovery 
and 
cooling 
down  
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2.4. Urine Analysis  
 
Urine  samples,  collected  just  before  the  test  started,  were  analysed  for 
osmolality  by  freezing  point  depression  (Micro-osmometer  3300,  Vitech 
Scientific, West Sussex, U.K.). Urine analysis was carried out in duplicates. 
 
2.5. Blood Analysis 
 
Blood was drawn into dry syringes and 10 ml dispensed into a tube containing 
K3EDTA.  The  blood  from  these  tubes  was  analysed  for  Hb  by  the 
cyanmethaemoglobin method (Sigma, Chemical Company Ltd., Dorset, U.K.) and 
packed cell volume (PCV) by the conventional microhaematocrit (Hct) method 
using microhaematocrit centrifuge (Hettich Mikro 22R- Microcentrifuge, Andreas 
Hettich GMBH & Co. KG, Tuttingen, Germany) and HAWAKSLEY capillary tubes 
and  HAWAKSLEY  reader  for  the  microhaematocrit  centrifuge  (Hawaksley  and 
sons Ltd, Sussex, UK). Haemoglobin (Hb) analysis was carried out in duplicate 
and Hct or PCV was carried out in triplicate.  
 
2.6. Reticulocytes 
 
Reticulocytes  parameters  were  analysed  using  a  haematology  analyser  (ABX 
Pentra 120, France) and measured as an absolute concentration value that is 
converted then presented as % reticulocytes (%Retics). 
 
2.7. OFF-hr Score 
 
OFF-hr score was calculated using the following second generation OFF-hr score 
equation: 
 
OFF-hr = Hb - 60√ (Ret)       (Gore et al; 2003) 
 
Whereas Hb represents haemoglobin concentration [g.L
-1] and Ret represents [%] 
Reticulocytes (Gore et al., 2003). 
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2.8. Data Analysis 
 
Data were expressed as the mean ± s.d. following a test for the normality of 
distribution. Statistical analysis was carried out using two factors mixed model 
ANOVA with repeated measures, followed by a simple main effects analysis for 
two-way  interactions.  In  addition,  the  magnitude  of  change  (∆)  between 
experimental trials was examined using a paired t-test when significance was 
identified using the simple main effects analysis. All statistical procedures were 
completed using SPSS for Windows version 15.0 (SPSS, Inc., Chicago, IL, USA). 
Statistical significance was declared at (P<0.05). 
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CHAPTER 3 
 
RESULTS 
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3. Results 
 
3.1. Creatine and Glycerol Hyperhydration Experiment (EXP1) 
 
3.1.1. Creatine Responders  
 
All Subjects were responders to Cr supplementation with increased body mass 
≥0.2 kg (Kilduff et al., 2003;  Easton et al., 2007). 
 
3.1.2. Body mass and water compartments 
 
Body mass did not change between familiarisation and pre-supplementation tests 
(P=0.53) (figure 3.1.). There was a significant increase in body mass after Cr and 
Gly supplementation by 0.82 ± 0.22 kg compared to pre-supplementation test 
(P<0.05).  TBW  increased  significantly  after  supplementation  by 0.67  ±  0.17  L 
(P<0.05)  with  no  changes  recorded  between  familiarisation  and  pre-
supplementation tests (P=1.000) (figure 3.1.). ECW increased significantly after 
supplementation  by  0.35  ±  0.09  L  (P<0.05)  with  no  changes  between 
familiarisation  and  pre-supplementation  (P=1.000)  (figure  3.1.).  There  was  a 
significant increase in ICW following hyperhydration by 0.37 ± 0.15 L (P<0.05) 
whereas  no  changes  were  noticed  between  familiarisation  and  pre-
supplementation tests (P=0.285) (figure 3.1.).   
 
3.1.3. Urine Osmolality 
 
Urine osmolality was significantly higher following Cr and Gly supplementation 
compared to the pre-supplementation tests (471 ± 252 mOsmol.kg
-1 vs. 632 ± 137 
mOsmol.kg
-1 respectively, P<0.05) (figure 3.2.) There was no difference in urine 
osmolality between familiarisation and pre-supplementation test (P=0.877).  
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Figure  3.1.  Change  in  Body  Mass  and  Water  Compartments  (n=8).  Comparisons  between 
Familiarisation  and  Cr/Gly  Pre-supplementation  Tests  ( ).  Comparisons 
between  Cr/Gly  Pre-supplementation  and  Cr/Gly  Post-supplementation  Tests 
( ).  Body  Mass  (BM).  Total  Body  Water  (TBW).  Extracellular  water  (ECW). 
Intracellular Water (ICW). Significant Change (*). 
  
 
 
 
 
 
 
Figure 3.2. Change in mean Urine  Osmolality  (n=8). Comparisons between Familiarisation 
(Fam)  Cr/Gly  Pre-supplementation  (Pre)  and  Cr/Gly  Post-supplementation  (post)  Tests. 
Significant Change (*). 
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3.1.4. Haemoglobin (Hb) and Haematocrit (Hct) 
 
Hb  did  not  change  significantly  at  anytime  between  familiarisation  and  pre-
supplementation tests (P=0.974) (figure 3.3.). There were noticed reduction in 
Hb concentrations following Cr and Gly hyperhydration supplementation but it 
did  not  reach  statistical  significance  when  compared  to  pre-supplementation 
test  (P=0.07).  Hct  did  not  change  significantly  at  anytime  between 
familiarisation and pre-supplementation tests (P=0.38) (figure 3.3.). However, 
after hyperhydration supplementation with Cr and Gly, there were significant 
reductions in Hct values when compared to pre-supplementation test (P<0.05).  
 
There  were  significant  decreases  comparing  the  individual  equivalent  blood 
samples of pre-supplementation to post-supplementation tests (i.e. comparing 
the first blood sample of pre-supplementation test vs. the first blood sample of 
post-supplementation test and so on for the rest of the collected samples). In 
the 10 min blood sample, Hct showed high significant reduction by 1.26% ± 0.65% 
(P<0.05). In the 20 min blood sample, there was also a high significant decrease 
of Hct by 1.3% ± 0.96% (P<0.05). However, there was a higher significant change 
noticed in the 30 min blood sample comparing pre-supplementation and post-
supplementation tests with a decrease in Hct by 1.36% ± 0.73% (P<0.05). 
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Figure  3.3.  Change  in  mean  Haemoglobin  (Hb)  and  Haematocrit  (Hct)  (n=8).  Comparisons 
between  Familiarisation  (Fam)  Cr/Gly  Pre-supplementation  (Pre)  and  Cr/Gly  Post-
supplementation Tests (Post). Subjects’ samples obtained at 10, 20 and 30 minutes of Supine 
Posture. WADA’s and International Sports Federations Haematological Cut-Off Values (---). 
Significant Change (*). 
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3.2. Postural Changes Experiment (EXP2)  
 
3.2.1. Haemoglobin (Hb) and Haematocrit (Hct) 
 
Hb  and  Hct  increased  significantly  (P<0.05)  with  the  change  of  posture  from 
supine to sitting and then to standing (figure 3.4.). Both Hb and Hct did not 
change  significantly  throughout  the  30  min  period  of  each  individual  posture 
(P=0.09 and P=0.24, respectively). 
 
At the first 10 min blood sample, Hb concentration values increased significantly 
by 0.55 ± 0.06 g.L
-1 when subjects changed their posture from supine to sitting 
(P<0.05).  Hb  concentration  increased  significantly  by  0.71  ±  0.14  g.L
-1  when 
posture  was  changed  from  sitting  to  standing  (P<0.05).  There  was  also  a 
significant increase in Hb concentration by 1.27 ± 0.2 g.L
-1 comparing the values 
of the supine to standing posture (P<0.05). Hct values of each posture at the 
first 10 min blood sample showed a significant increase by 0.87% ± 0.12% when 
subjects  changed  their  posture  from  supine  to  sitting  (P<0.05).  Hct  values 
showed significant increase by 1.70% ± 0.08% when posture was changed from 
sitting to standing posture (P<0.05). There was also a significant increase in Hct 
by 2.57% ± 0.04% comparing values of supine to standing posture (P<0.05). 
 
In the second sample of each posture, i.e. 20 min blood samples, Hb increased 
significantly when subjects changed their posture from supine to sitting 0.85 ± 
0.15 g.L
-1 (P<0.05). Hb also showed a significant increase when posture changed 
from sitting to standing by 0.76 ± 0.02 g.L
-1 (P<0.05). There was a significant 
change comparing the shift of supine to standing postures with increased values 
by 1.61 ± 0.16 g.L
-1 (P<0.05). Hct values of each posture at the 20 min blood 
sample increased significantly when posture was changed from supine to sitting 
1.41% ± 0.25% (P<0.05) and also increased significantly when posture changed 
from sitting to standing by 1.70% ± 0.3% (P<0.05). There was a significant change 
in Hct comparing the shift of supine to standing postures with increased values 
by 3.12% ± 0.04% (P<0.05). 
 
In the third sample of each posture, i.e. 30 min blood samples, Hb increased 
significantly when posture changed from supine to sitting by 0.78 ± 0.36 g.L
-1   
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(P<0.05)  and  when  posture  changed  from  sitting  to  standing,  Hb  changed 
significantly showing an increase by 0.94 ± 0.15 g.L
-1 (P<0.05). The increase of 
Hb was also significant when comparing the values of supine to standing posture 
1.72 ± 0.37 g.L
-1 (P<0.05). Hct values of each posture at the 30 min blood sample 
increased significantly when posture changed from supine to sitting by 1.70% ± 
0.21% (P<0.05) and when subjects changed their posture from sitting to standing 
Hct  showed  significantly  increased  values  by  1.97%  ±  0.28%  (P<0.05).  The 
increase of Hct was also very highly significant when comparing the values of 
supine to standing posture 3.67% ± 0.07% (P<0.05). 
 
Looking at the individual data (figure 3.5.) none of the 10 subjects exceeded the 
50% Hct cut-off whereas only 2 subjects exceeded the 17 g.L
-1 Hb cut-off at 
some  point  in  one  or  more  postures.  The  first  subject’s  blood  samples  Hb 
exceeded the cut-off at the last 2 blood samples of the standing posture with 
values of 17.25 g.L
-1 and 17.75 g.L
-1, respectively. The second subject’s blood 
samples exceeded the Hb cut-off at all postures. This subject’s supine posture 
blood sample had Hb concentration of 17.2 g.L
-1 only at the 30 min sample. 
However, the second subject had the same reading of 17.1 g.L
-1 at the whole 
time course of  the  sitting  posture.  At  the  standing  posture,  this  subject  had 
exceeded the cut-off by the following Hb concentration values of 18.25 g.L
-1, 
18.35 g.L
-1 and 18.2 g.L
-1, respectively.  
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Figure 3.4. Change in mean Haemoglobine and Haematocrit (n=10). Comparisons between 
subjects’  blood  samples  (Haemoglobin  and  Haematocrit)  at  Supine,  Sitting  and  Standing 
Postures.  Subjects’  blood  samples  obtained  at  10,  20  and  30  minutes  of  each  posture. 
WADA’s and International Sports Federations Haematological Cut-Off Values (---). Significant 
Change (**). 
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Figure 3.5. Change in individual Haemoglobin and Haematocrit values (n=10). Comparisons 
between individual subjects’ blood samples (Haemoglobin and Haematocrit) at Supine, Sitting 
and Standing Postures. Subjects’ blood samples obtained at 10, 20 and 30 minutes of each 
posture. WADA’s and International Sports Federations Haematological Cut-Off Values (---). 
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3.3. Running with creatine and Glycerol Hyperhydration 
Experiment (EXP3) 
 
3.3.1. Creatine Responders 
 
All Subjects were responders to Cr supplementation with increased body mass 
≥0.2 kg (Kilduff et al., 2003;  Easton et al., 2007); except for one subject who 
only gained 0.15 kg after the supplementation trail. 
 
3.3.2. Haemoglobin (Hb) and Haematocrit(Hct) 
 
Hb and Hct did not change significantly at any point comparing all samples using 
general linear model with hyperhydration and time factors (P=0.74 and P=0.76, 
respectively) (figure 3.6.).  
 
3.3.3. Reticulocytes (% Retics) 
 
Reticulocytes (%Retics) did not change significantly at any point comparing all 
samples  using  general  linear  model  with  hyperhydration  and  time  factors 
(P=0.72) (figure 3.7.). 
 
3.3.4. OFF-hr Scores 
 
OFF-hr Scores did not change significantly at any point comparing all samples 
using general linear model with hyperhydration and time factors (P=0.78) (figure 
3.7.). 
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Figure  3.6.  Change  in  mean  Haemoglobin  (Hb)  and  Haematocrit  (Hct)  before 
( )  and  after  ( )  Cr/Gly  Supplementation 
hyperhydration; at rest, post exercise at 10°C and post exercise at 35°C (n=7). WADA’s and 
International Sports Federations Haematological Cut-Off Values (---). Athlete subjects’ blood 
samples obtained at 10 minutes of Sitting Posture (WADA’s Standards). 
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Figure 3.7. Change in mean Reticulocytes (Retics) and OFF-hr scores (2
nd generation model 
from  Gore  et  al.,  2003)  before  ( )  and  after  ( ) 
Cr/Gly Supplementation hyperhydration; at rest, post exercise at 10°C and post exercise at 
35°C (n=7). WADA’s and International Sports Federations Haematological Cut-Off Values (---). 
Athlete  subjects’  blood  samples  obtained  at  10  minutes  of  Sitting  Posture  (WADA’s 
Standards).  
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4. Discussion 
 
4.1. General Discussion  
 
The haematological cut-off values used in the three experiments accomplished 
in this thesis (i.e. EXP1, EXP2 and EXP3) refer to male subjects and athletes only 
and the discussion will be focused on male cut-off values and scores. The cut-off 
values  of  the  haematological  parameters  and  markers  are  used  by  some 
federations in collaboration of IOC and WADA to control and limit the abuse of 
prohibited substances and methods. This is prevalent in endurance sports and 
competitions where it is difficult to detect the doping substances like rHuEPO or 
doping methods like autologous blood transfusions. The first federation to apply 
the  no-start  rule  was  the  UCI  when  blood  doping  was  out  of  control  and 
causalities  and  mortalities  were  witnessed  in  sports  and  competition  fields 
among cyclists. For general health and safety reasons of the competing cyclists, 
the cut-off (highest) value of Hct was set at and not to exceed 50% for males and 
47% for females. This cut-off value was especially set to avoid the complications 
of  high  blood  viscosity  of  some  elite  cyclists  during  endurance  cycling 
competitions, albeit a  result  of  having naturally  high  Hct  or  elevated  Hct by 
legal methods and substances (altitude training and supplements), or illegally by 
autologous blood transfusions and rHuEPO injections. However, WADA have not 
yet set any haematological cut-offs for “no- start” or “start prohibition” rules in 
the World Anti-Doping Code and the only purpose of blood testing for uses in 
blood doping substances are for blood substitutes, serum EPO and the ON model 
score of second generation model (Gore et al., 2003). The use of a positive ON 
model score of blood test acts as a pre-EPO urine test and confirmatory protocol 
due  to  the  economically  high  costs  and  length  of  time  spent  to  process  and 
analyse urine samples.  
 
Currently,  some  other  haematological  parameters  cut-off  values  have  been 
added  and  documented  in  some  federations’  general  practice  and  regulation 
documents  and  Anti-Doping  rules  with  compliance  to  the  World  Anti-Doping 
Code. For example, Hct, Hb, %Retics and OFF-hr score of (Gore et al., 2003) 
second  generation  model  and  HbZscore  and  OFF-hrZsore  the  longitudinal 
haematological  monitoring  (Sharpe  et  al.,  2006)  third  generation  model.  The  
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International Cycling Union (UCI) medical monitoring and medical tests results 
for  sporting  safety  and  conditions  states  in  chapter  13  articles  13.1.062  and 
13.1.63 that the athlete is considered unfit to compete and participate in UCI 
approved cycling events if Hct >50% with Hb >17 g.L
-1 for males and Hct >47% 
with Hb >16 g.L
-1 for females, OFF-hr score >133 for males and >123 for females 
and %Retics <0.2% and >2.4% for both males and females (UCI, 2009). For cyclists 
who  have  naturally  high  Hct  values  (50%  for  males  and  47%  for  females),  an 
international  certificate  should  be  issued and  at  least  4  blood  tests  within  6 
weeks or 4 annual blood tests conducted. According to article 13.1.089, athletes 
who do not submit to the medical monitoring should provide a medical check up 
file  from  a  haematologist  and  obtain  a  UCI  certificate  for  naturally  high  Hct 
(UCI, 2009).  
 
The international Ski Federation (FIS) did not consider the Hct in the FIS Anti-
Doping Rules document and set the Cut-Offs for Hb, %Retics, OFF-hr score and 
with  the  addition  of  HbZscore  and  OFF-hrZsore.  If  FIS  registered  and  licensed 
athletes have the following: Hb ≥17 g.L
-1 for males and Hb ≥16 g.L
-1 for females, 
%Retics <0.2% and >2% for both males and females; and OFF-hr scores ≥125.6 for 
males and ≥113.5 for females and HbZscore and OFF-hrZsore ≥3.09 then they are 
obliged to undergo “start prohibition” rule, according to FIS Anti-Doping Rule 
article FIS B.4.1 to B.4.3, if they (FIS, 2009).  
 
The International Associations of Athletics Federations (IAAF) has set the Hct, Hb 
and  %Retics  and  OFF-hr  scores  cut-offs  according  to  the  previous  scientific 
research and similar to that of UCI cut-offs but without direct “start prohibition” 
rule.  The  reason  for  not  applying  the  “start  prohibition”  or  “no-start”  rules 
might be because of the naturally and abnormally high blood profiles of certain 
leading  champion  athletes  with  consistent  dominance  in  endurance  and  long 
distant running, specifically East African runners  (Ojiambo et al., 2008;  Moore 
et al., 2007;  Parisotto et al., 2000b). The cut-offs applied are as follows: Hct 
>50% for males and Hct >47% for females, Hb >17 g.L
-1 for males and Hb >16 g.L
-1 
for females, % Retics <0.2 % and >2.0 % for both males and females and OFF-hr 
>133 for males and >123 for females. If these are exceeded, the athlete should 
provide  a  urine  sample  for  screening  of  prohibited  substances  (IAAF,  2009;  
Ojiambo et al., 2008;  Moore et al., 2007) before banning, or apply the “no-  
 
76 
start” rule to their athletes which follow the WADA’s standard rules for banning 
athletes  and  act  like  a  pre-EPO  urine  test  as  aforementioned  (WADA,  2001;  
WADA,  2009b).  WADA  is  currently  considering  the  abnormal  haematological 
profiles and cut-offs of OFF-hr sores (Gore et al., 2003) and HbZscore and OFF-
hrZsore values (Sharpe et al., 2006) as stated by Ojiambo et al. (2008). 
 
Previous studies conducted in our laboratories showing the synergistic effects of 
the hyperhydration induced by ingesting Cr and Gly (Easton et al., 2007;  Easton 
et al., 2006) succeeded in increasing subjects’ plasma volume. The same fluid 
loading protocol has been replicated in EXP1 except for the time and posture at 
which  blood  samples  were  withdrawn.  Easton  et  al.,  (2007)  obtained  blood 
samples  every  10  min  for  40  min  from  the  subjects  whilst  seated  on  cycle 
ergometer and Easton et al., (2006) obtained blood from the subjects after 15 
min of seated position. The authors of both studies obtained the blood samples 
from a superficial vein located on the dorsal surface of the hand while in EXP1 
the blood was withdrawn from the anticubital vein as done by previous leading 
research on blood and EPO doping (Parisotto et al., 2001;  Sharpe et al., 2002;  
Ashenden et al., 2003). Easton et al., (2007) and Easton et al., (2006) used the 
same methods to calculate plasma volume changes from the changes in Hct and 
Hb  (Dill  and  Costill,  1974)  of  pre-supplementation  trials  in  relation  to  post-
supplementation trials with the assumption that there were no changes in RBCs 
during  the  seven  days  of  Cr  and  Gly  supplementation  period.  Therefore,  the 
decreases  in  Hct  and  Hb  values  found  in  EXP1  were  the  consequence  of 
hyperhydration  which  was  generated  by  supplementation  of  Cr  and Gly  for  7 
days representing the reductions in plasma volume and vice versa (Easton et al., 
2009).  
 
Body  mass  increase  (figure  3.1.)  in  EXP1  represents  water  retention  and  as 
indirect measurement of such retention induced by the ingestion of Cr and Gly 
(Easton et al., 2007). TBW increased significantly in EXP1 (figure 3.1.) after Cr 
and Gly supplementation for 7 days by 0.67 ± 0.17 L (P<0.05). The addition of 
Gly to Cr supplementation for 7 days in EPX1 may overcome the phenomenon of 
having non-responders to Cr as all subjects have gains of more than 0.2 kg body 
mass compared to a previous study in which Cr non-responders were reported 
(Kilduff  et  al.,  2003).  It  is  well  known  that  Gly  increases  ECW  (Nelson  and  
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Robergs, 2007;  Koulmann et al., 2000) while Cr raises ICW (Kilduff et al., 2004). 
However Cr played the major role in this fluid retention process as the ICW was 
greater than ECW which was induced by the effect Gly ingestion (figure 3.1.).  
 
In EXP1 (figure 3.3.), Hct values in all 3 blood samples during the 30 min supine 
laying were decreased significantly by the effects of the induced hyperhydration 
of  Cr  and  Gly  ingestion,  whilst  there  were  no  significant  reductions  in  Hb 
concentration  (P=0.07).  Hb  is  located  within  RBCs  and  considered  as  an 
intracellular molecule. Theoretically any increases in ICW compartment should 
affect  the  concentration  of  its  content  including  Hb  molecules  concentration 
(Easton  et  al.,  2007;    Dill  and  Costill,  1974;    Nelson  and  Robergs,  2007). 
However, this was not the case in EXP1 even when the major increase in TBW 
influenced the raise in ICW. In contrast, Hct, which is known as pack cell volume 
and represents the percentage RBCs in whole blood that is located within the 
vessels and considered as an extracellular fluid (Easton et al., 2007;  Dill and 
Costill,  1974;    Nelson  and  Robergs,  2007),  was  highly  affected  by  such 
hyperhydration and the increase in ECW which was considered minor compared 
to the water retained within ICW.  
 
The 10 min blood sample results from EXP1, showed a significant reduction by 
1.26%  ±  0.65%  (P<0.05)  in  Hct.  With  the  progression  of  time  at  the  supine 
posture  of  EXP1  (figure  3.3.),  the  30  min  blood  sample  showed  a  greater 
reduction  of  Hct  values  of  1.35%  ±  0.73%  (P<0.05)  proving  the  effects  of 
prolonged  supine  posture  and  hyperhydration  on  haemodilution.  The  supine 
posture of EXP1, in which blood samples were withdrawn, has been previously 
used  by  leading  research  studies  on  EPO  and  blood  doping  in  the  process  of 
inventing  the  first  and  second  generation  models  to  detect  such  prohibited 
substances and methods but the samples were taken at 5 min and did not exceed 
10 min. (Parisotto et al., 2000a;  Parisotto et al., 2001;  Ashenden et al., 2001;  
Sharpe  et  al.,  2002;    Ashenden  et  al.,  2003).  The  authors  of  these  studies 
emphasised the effects of prolonged supine posture on blood parameters and 
markers of blood doping. These reduced Hct values in all 3 blood samples of 
EXP1  suggest  may  result  in  false  negatives  of  athletes’  blood  samples. 
Particularly, endurance athletes with abnormally and illegally Hct values equal 
or slightly higher than the 50% Hct cut-off value can abuse such hyperhydration  
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and posture protocols when being tested on the year round monitoring program, 
to  create  haematological  passports  (out-,  pre-  and  in  competitions),  where 
“start prohibition” or “no-start” rules are applied by federations. For athletes 
with naturally high Hct values, this hyperhydration protocol of EXP1 could be 
used as a safe method in preventing high blood viscosity which can occur during 
prolonged exercise and endurance events. 
 
Gly and Cr ingestion has been found to reduce excreted urine volume and output 
(Anderson et al., 2001;  Hultman et al., 1996). Urine osmolality in EXP1 (figure 
3.2.)  increased  significantly  by  supplementing  with  Cr  and  Gly  (632  ±  137 
mOsmol.kg
-1; P<0.05). This increased osmolality is very effective and beneficial 
for  selected  tested  athletes  prior  to  providing  urine  sample.  Diluted  urine 
samples are rejected or suspended and the athletes are not allowed to leave the 
doping station without providing a urine sample of the required concentration. 
As stated by WADA in  the Guidelines for Urine Sample Collection; article 5.11.11 
that ”The DCO (Doping Control Officer) shall confirm that the sample meets 
the  requirements  for  analysis,  as  specified  by  the  ADO  (Administrative 
Doping officer) in accordance with the laboratory standards, by testing the 
residual  volume  of  urine  remaining  in  the  collection  vessel  for  specific 
gravity (greater than or equal to 1.005 if using a refractometer, or 1.010 
with  lab  sticks,  or  as  specified  by  the  relevant  laboratory)  and,  if 
necessary, pH (between 5 and 7, or as specified by the relevant laboratory). 
Reagent strips and/or a refractometer may be used.” (Guidelines for Urine 
Sample  Collection  WADA,  2004;    World  Anti-Doping  Code  WADA,  2009b).  This 
supplementation  protocol  in  EXP1  has  such  an  advantage  over  other 
hyperhydrating drinks that may result in decreased water retention and diluted 
urine  sample.  The  time  after  notifying  the  athlete  to  arrive  to  the  Doping 
Control Station and provide a urine sample ranges between 30 min to 60 min 
especially  for  in-competition  samples  (Guidelines  for  Urine  Sample  Collection 
WADA,  2004;    World  Anti-Doping  Code  WADA,  2009b).  Athletes,  especially 
endurance athletes, delaying to provide their urine samples for any reason is 
very favorable in preventing false positives of r-HuEPO doping (Beullens et al., 
2006). Doing such a strategy accompanied by hyperhydration protocol used in 
EXP1 can ensure the time to provide concentrated urine sample and avoidance 
of suspicion of r-HuEPO abuse, which may result in suspensions and penalties.  
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These strategies are not to encourage blood doping but to help clean athletes 
form some of the complications occurring in the Doping Control Stations in an 
attempt to provide a prompt urine sample according to WADA standards.  
 
The increase in muscular ICW is induced by Cr loading supplementation due to 
the ability of Cr to create an osmotic gradient within the cells that draws the 
water  from  the  extracellular  compartment  and  intercellular  space  into  the 
intracellular compartment (Kilduff et al., 2003;  Kilduff et al., 2002;  Mesa et 
al., 2002). The decrease in the excreted urinary volume is also associated with 
Cr supplementation especially in the initial days of Cr ingestion (Hultman et al., 
1996). This water retention was only considered an adverse side effect when Cr 
supplementation  was  used  only  as  an  ergogenic  aid  in  sports  with  high  and 
maximal intensity nature of exercise due to the accompanied increase in body 
mass (Bemben and Lamont, 2005). However, water retention and hyperhydration 
effects of Cr ingestion have been used and are currently being applied in many 
situations  for  positive  gain.  For  example,  endurance  type  sports,  prolonged 
exercise and different environmental situations that have certain homeostatic 
effects on the athletes hydration status (Easton et al., 2007;   Kilduff et al., 
2004;  Hadjicharalambous et al., 2008;  Vogel et al., 2000) and in other medical 
purposes like the prevention of orthostatic intolerance and possible treatment of 
pre-syncope and syncope (Easton et al., 2006;  Easton et al., 2009).  
 
Hyperhydration and water retention induced by Cr supplementation can affect 
plasma volume. Sixteen subjects were supplemented with either Cr or placebo 
(Vogel et al., 2000) prior to cycling on a cycle ergometer for 160 minutes (at 
32°C  with  50%  relative  humidity)  totally  to  induce  a  hypohydration  status. 
Significant reductions were found in plasma volume in both groups, with higher 
losses in the placebo group (-9%) than Cr group (-7%) as well as losses in body 
mass which were higher in placebo group (-4%) than Cr group (-2.5%) compared 
to pre-test plasma volume and body mass (Vogel et al., 2000). In contrast, there 
were no significant increases in plasma volume in 21 subjects between placebo 
and  Cr  group  in  a  study  by  Hadjicharalambous  et  al.  (2008)  with  similar  Cr 
supplementation and exercise conditions as Vogel et al.(2000) which included 20 
g.day
-1  +  140  g.day
-1  glucose  for  7  days  on  cycle  ergometer  for  40  min  at 
temperature of ≈30°C with ≈70% relative humidity (Hadjicharalambous et al.,  
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2008). Although, there were no changes in plasma volume between the 2 groups 
post-supplementation TBW and body mass were significantly higher in Cr group 
as well as there being a tendency for ICW to be higher, although this did not 
reach  statistical  significance  (Hadjicharalambous  et  al.,  2008).  Easton  et  al. 
2007  tested  24  subjects  with  a  similar  Cr  loading  dosage,  environmental 
conditions  and  length  of  exercise  with  the  addition  of  Gly  supplementation 
groups  (Easton  et  al.,  2007)  to  the  above  studies  with  4  combinations  of 
supplementation groups as follows: placebo/placebo, Placebo/Gly, Cr/Placebo 
and  Cr/Gly.  Plasma  volume  did  not  significantly  change  following 
supplementation  and  post-exercise  in  any  groups.  There  were  significant 
hyperhydration and increases in body mass, TBW, ICW and ECW in all groups 
except for placebo/placebo group and ECW in Cr/Placebo group (Easton et al., 
2007).  The  latter  finding  emphasises  the  effect  of  Cr  supplementation  on 
increasing ICW with no influence on ECW.  
 
Cr  supplementation  has  been  shown  to  influence  body  mass  and  TBW  via 
increasing ICW. However, few factors may disrupt this response. The first factor 
is how well Cr is dissolved in the supplement fluid. The second factor is the 
intake of caffeine (Vandenberghe et al., 1996) and other diuretics on the lost 
retained water in urine. All the subjects of EXP1, EXP2 and EXP3 refrained from 
consuming  caffeinated  drinks  in  the  test  days.  The  third  factor  is  how  Cr 
individual  respond  positively  or  neutrally  to  Cr  supplementation  in  the 
intramuscular uptake of ingested Cr which follows certain criteria Greenhaff et 
al. was the first to categorise Cr supplemented subjects into “responders” and 
“non-responders” (Greenhaff et al., 1994). Muscle biopsies were obtained from 8 
subjects’s  quadriceps  muscle  and  precisely  vastaus  lateralis  after  isometric 
exercise pre- and post-supplementation with Cr at a dose of 20 g.day
-1 for 5 
days. Muscle PCn, free Cr and total Cr (PCn +free Cr) were measured from the 
freeze  dried  biopsies  as  mmol.kg
-1  dry  matter.  From  the  results  of  the 
concentration  of  total  muscle  Cr,  subjects  were  then  categorised  as 
“responders” (total Cr ≤120 mmol.kg
-1 dry matter) and “non-responders” (total 
Cr ≥120 mmol.kg
-1 dry matter). The responders had lower pre-supplementation 
total  Cr  and  better  muscular  PCr  resynthesis  and  Cr  uptake  during  recovery 
periods after exercise bouts (Greenhaff et al., 1994). Kilduff et al. used similar 
criteria but the total intramuscular Cr was calculated from urine samples of 32  
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subjects  which  were  estimated  and  corrected  for  the  excreted  creatinine  in 
urine (Kilduff et al., 2002). Total intramuscular Cr uptake was calculated from 
subtracting the supplemented Cr daily dosage from urinary excreted Cr which 
was creatinine corrected. The subjects were categorised as “responders” (total 
Cr  ≥32  mmol.kg
-1.dry  weight  muscle)  and  “non-responders”  (total  Cr  ≤21 
mmol.kg
-1.dry  weight  muscle)  after  5  days  of  Cr  supplementation  (20  g.day
-1 
+180  g.day
-1  dextrose)  compared  to  placebo  group  (200  g.day
-1  dextrose) 
followed by isometric exercise. The results showed increased fat free mass, body 
weight, TBW, peak and total force in the Cr responders compared to placebo 
group (Kilduff et al., 2002). In another study by Kilduff et al., the same method 
was used to estimate the total intramuscular Cr uptake (Kilduff et al., 2003). 
However,  another  criterion  was  added  in  this  to  the  phenomenon  of  Cr 
supplementation  responder  subjects  with  optimal  intramuscular  uptake. 
Subjects were considered Cr “responders” if they gained >0.2 kg compared to 
their pre-supplementation body mass (Kilduff et al., 2003). In this study, Cr was 
supplemented  over  4  weeks  period  and  compared  placebo  and  total  Cr  was 
calculated before and after isokinetic and isometric exercises in 19 subjects. 
Placebo  and  Cr  supplemented  groups  underwent  two  distinctive  loading  and 
maintenance  phases  which  consisted  of  7  and  21  days  respectively.  In  the 
loading phase, Cr was supplemented at a dose of 20 g.day
-1 Cr + 140 g.day
-1 
glucose  whereas  placebo  was  supplemented  as  160  g.day
-1  glucose.  The 
maintenance phase started from the eighth day until the end of the four weeks 
in which Cr group was supplemented with 5 g.day
-1 Cr + 35 g.day
-1 glucose and 
placebo  group  ingested  40  g.day
-1  glucose.  The  results  showed  significant 
ergogenic  and  hyperhydration  improvements  in  the  “responders”  who  had 
greatest  body  mass  increases  >0.2  kg  associated  with  the  highest  estimated 
intramuscular  Cr  uptake  values  (Kilduff  et  al.,  2003).  The  improvements  in 
hyperhydration status due to water retention (caused by Cr supplementation) 
was  the  highest  in  the  “responders”  which  resulted  in  dramatic  significant 
increases  in  TBW  that  was  affected  by  the  significant  increases  in  ICW 
(intracellular  water  retention)  without  significant  effects  on  ECW  condition 
(Kilduff  et  al.,  2003).  This  notion  of  differentiating  subjects  into  Cr 
supplementation “responders” from “non-responders” were also used in another 
published study that was based on post-supplementation body mass increases of  
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>0.2 kg (Easton et al., 2007). In EXP1, all the 8 subjects were responders to Cr 
with gains over 0.2kg.  
 
On the other hand, Gly influences the increases in ECW more than ICW (Easton 
et al., 2007). Gly acts more efficiently as a hyperhydating agent and supplement 
for its hyperosmotic properties and its distribution among all fluid compartments 
which is enhanced when accompanied with further ingestion of water volumes 
(Nelson  and  Robergs,  2007).  Furthermore,  the  direct  effects  of  Gly  on  the 
kidneys to reabsorb the excess water from the circulation via raising the renal 
medullary  concentration  (osmotic)  gradient  is  the  actual  mechanism 
independent of hormonal reactions and responses by which Gly works, produces 
and induces measured hyperhydration (Freund et al., 1995;  Melin et al., 2002). 
Gly  is  primarily  reabsorbed through  the  renal  proximal  convoluted  tubule  via 
passive diffusion (Kruhoffer and Nissen, 1963) and may also have a contribution 
from  active  transport  (McCurdy  et  al.,  1966).  The  hormonal  mechanisms, 
responses  and  reactions  of  the  antidiuretic  hormone  (ADH),  aldosterone  and 
natriuretic peptide (ANP) that induce renal water reabsorption is not affected 
and can not be applied with Gly ingestion (Freund et al., 1995). Melin et al. also 
tested the hormonal and renal responses of the hyperhydration induced by 1.1 
g.kg 
-1 of body weight of Gly supplementation which was mixed with fluid in 
eight healthy subjects and also concluded that there were no significant changes 
in the concentration of plasma ADH, ANP, rennin and aldosterone (Melin et al., 
2002). In addition, these authors also stated that renal responses to retain fluids 
and  induce  hyperhydration  (assessed  by  bioelectrical  impedance)  is  by  the 
effects of Gly ingestion rather than these fluid-regulating hormones (Melin et 
al., 2002). Furthermore, Gly ingestion with additional fluids intake decreased 
the  rate  by  which  free  water  is  cleared  from  the  circulation  (Freund  et  al., 
1995).  Gly  turnover  (Bortz  et  al.,  1972)  plays  a  major  role  in  offsetting  the 
efficiency of the gained hyperhydration and fluid retention which provides the 
need for regular supplementation of periodic and regular Gly doses to maintain 
that hyperhydration status (Bortz et al., 1972;  Nelson and Robergs, 2007). The 
regular supplementation of Gly at a dose of 1.0 g.kg 
-1 body mass twice daily 
(once  in  the  morning  and  once  in  the  evening)  showed  significant  gains  and 
increases  plasma  volume  which  was  explained  by  the  increase  in  TBW  and 
specifically in the ECW compartment (Easton et al., 2006;  Easton et al., 2007).  
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These findings supports the results of EXP1 that leaded to decreased Hct and Hb 
compared to the results of EXP3 which will be discussed shortly.  
 
The significant change in Hb and Hct (P<0.05) was noticed upon alternating the 
posture from supine to sitting and ending with standing which was influenced by 
the progression in time of each posture in EXP2 (figure 3.4.). However, there 
was no recorded change of Hb and Hct between the 3 blood samples within each 
individual  posture  (P=0.09  and  P=0.24,  respectively).  The  standing  posture  in 
EXP2 served as a control posture for both the supine and sitting postures. The Hb 
and Hct values of the standing posture were significantly (P<0.05) higher than 
the supine and sitting postures. The standing posture causes the blood to pool 
distally in the lower limbs by the effects of gravitational pull and the limited 
venous  return  to  lower  limbs.  Venous  return  can  be  enhanced  by  increasing 
muscular contraction. In EXP2, the subjects were advised to minimise the calf 
muscles  contractions,  ankles  and  feet  movements  unless  they  were  very 
uncomfortable. Similar results of increased Hb and Hct and decreased plasma 
volume  were  found  with  70°  and  60°  standing  in  tilt  table  (head  up  tilt) 
experiments (Easton et al., 2009;  Qi et al., 2005). This standing posture in EXP2 
resulted in higher values of Hb and Hct at the 30 min blood sample compared to 
the 20 min and 10 min blood samples.  
 
Throughout  all  the  supine  posture  period  of  EXP2    (figure  3.4.),  Hb  and  Hct 
values were decreasing with the progression of time but again did not change 
significantly when comparing these parameters of the 30 min blood sample to 
the 10 min blood sample. In contrast, Hb and Hct values of the sitting posture 
were increasing with the elapse of time and results were highest in the 30 min 
blood sample compared to the 10 min blood sample and this change was also 
insignificant.  These  dissimilar  physiological  responses  upon  the  duration  and 
time spent in each posture is mainly explained by partial blood pooling in the 
lower limbs in the sitting posture and the eliminated effects of the gravity forces 
on blood vessels and the functional and structural anatomy of the human body. 
The  minimum  significant  increases  in  Hb  and  Hct  noticed  in  sitting  posture 
compared to equivalent blood sample (i.e. 10 min sample) of the supine posture 
were 0.55 ± 0.06 g.L
-1 and 0.87% ± 0.12%, respectively (P<0.05). This raise in Hb 
and Hct shows that supine posture has a haemodiluting effect and potential to  
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expand  plasma  volume.  Therefore,  WADA’s  only  approved  posture  and  time 
which are sitting and withdrawal of blood at 10 min are very  acceptable. In 
addition, venipuncture in this posture is more visible to the selected athlete and 
his/her representative is more legally accepted according to WADA’s World Anti-
Doping Code and the guidelines of blood sample collection.  
 
Focusing on the individual Hb and Hct values of each subject (figure 3.5.), no 
subject exceeded the 50% Hct cut-off whereas only 2 subjects exceeded the 17 
g.L
-1  Hb  cut-off at  some  point  in  one  or more  postures.  This  implicates  that 
athletes having borderline Hb concentrations (naturally or legally) close to the 
Hb  cut-off  of  blood  samples  withdrawn  at  supine  posture  may  possibly  be 
included  in  suspicious  lists  or  prohibited  from  competing  in  official  sporting 
events where blood doping tests are applied by following WADA’s guidelines (i.e. 
sitting posture for 10 min). EXP2 shows that postural changes from supine (0°) to 
sitting and ending with standing posture has more effect and impression on Hb 
concentration than Hct% values. However, to make such a conclusion, endurance 
athlete  subjects,  possibly  with  higher  Hb  and  Hct  values  and  different 
competition disciplines, should be recruited with the same protocol and design 
of EXP2 and with the inclusion of more blood parameters and markers that may 
be affected by endurance performance and blood doping. 
 
The hyperhydration protocol in EXP3 differed slightly from EXP1 in which Gly was 
ingested at the test day and precisely 5 hours prior to the first blood sample. 
The addition of Gly to Cr at the seventh day of fluid loading protocol was to 
reduce the feeling of stomach fullness and the tendency to feel nauseous among 
the selected trained subjects in EXP3. All subjects in experiment 3 were actively 
involved  in  exercise training (some competed in  local  sporting  competitions). 
Using Gly for 7 consecutive days may delay their training programs caused by 
delayed  stomach  emptying  and  fullness.  The  posture  and  time,  which  were 
sitting and waiting for 10 min prior to blood sample withdrawal, of EXP3 were 
modified from EXP1 to match WADA’s only approved posture and time (WADA 
Standards and Harmonization Guidelines for Blood Collection WADA, 2008). The 
addition  of  2  exercise  bouts  of  30  min  running  once  in  slightly  cool  damp 
temperature (10°C with 70% relative humidity) and the other in warm humid 
temperature (35°C with 70% relative humidity) in an environmental chamber at  
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60%  of  their  VO2  max  to  mimic  the  physiological  effects  of  the  changes  of 
temperatures and endurance work exerted, with regard to time frame, in real 
exercise field on blood markers before and after hyperhydration.  
 
Gly  absorption  and  emptying  from  gastrointestinal  tract  is  usually  delayed, 
causing an acute dehydration explained by lower plasma volume for the shift of 
fluids  from  the  plasma  contained  in  the  circulating  blood  to  gastrointestinal 
tract where Gly is located (Easton et al., 2006;  Freund et al., 1995). However, 
this mechanism is transient and the duration depends on the concentration and 
dose of Gly and the volume of fluid ingested with it. The speed by which the 
gastrointestinal tract empties Gly is equivocal and still debatable that leaded to 
many  questioning  whether  Gly  is  effective  as  a  hyperhydrating  agent  and 
supplement. However, much of the varying results found in the literature may 
be explained by the different Gly hyperhydration protocols (e.g. with water or 
without), methods (e.g. before, after or without exercise) and concentrations 
which  have  been  used.  However,  much  of  the  work  done  in  our  laboratories 
using different timings of Gly ingestion protocols (e.g. 1 hour, 3 hours and 5 
hours) before testing (Easton et al., 2006) has overcome these methodological 
issues and concluded that it takes 5 hours for Gly to be totally absorbed and 
distributed  among  body  fluid  compartments  (especially  ECW)  to  induce 
hyperhydration  (Easton  et  al.,  2007).  The  use  of  Gly  supplementation  with 
exercise in hot environment have also been tested with the last dose (1.0 g.kg 
-1 
body mass) of Gly consumed with the addition of fluid 5 hours prior to testing 
(Easton et al., 2007). 
 
The  hyperhydration  protocol  and  blood  withdrawal  posture  before  and  after 
running in different temperatures used in EXP3 resulted in insignificant changes 
of  4  measured  and  calculated  blood  markers:  Hb,  Hct,  %Retics  and  OFF-hr  
comparing pre-supplementation to post-supplementation tests (figures 3.6. and 
3.7.). These results are thought to be by the influence of a single Gly bolus 
ingestion rather than for 7 days as in EXP1. Among these parameters, Hct had 
the highest tendency and sensitivity to decrease in EXP3 hyperhydration protocol 
and  posture.  Hb,  %Retics  and  OFF-hr  scores  were  not  affected  by  EXP3 
hyperhydration and posture protocols. In addition, %Retics post-supplementation 
values  at  rest  were  lower  at  rest  and  increased  after  both  running  bouts  
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compared to pre-supplementation. To prevent statistical errors, these statistical 
results and analyses were performed with and without the inclusion of a non-
responder  subject  to  Cr  supplementation  who  only  gained  0.15  kg  after  the 
supplementation  protocol;  as  mentioned  earlier  responders  to  Cr  loading 
supplementation are characterised by the increase in body mass ≥0.2 kg (Easton 
et al., 2007;  Kilduff et al., 2003). However, no significant changes in Hb, Hct, 
%Retics  and  OFF-hr  score  were  noticed  by  running  the  statistical  analysis  in 
either ways of including and excluding this non-responder subject’s data.  
 
Lyons et al. used Gly only to hyperhydrate 6 subjects with 1.0 g.kg 
-1 body mass 
3  times  within  4  hours  with  large  fluid  intake  prior  to  90  min  exercise  bout 
separated by 5 min rest at every 30 min interval in hot dray environment (42°C 
with 25% relative humidity) at 60% of subject’s VO2 max. The blood samples were 
withdrawn from the subjects in a sitting posture and Hb and Hct values showed 
no significant changes following Gly ingestion (Lyons et al., 1990). These results 
are in agreement of EXP1 hyperhydration loading protocol that contradicts the 
effects of Gly ingestion on the test day only as in EXP3. Easton et al. (2007) used 
the Cr and Gly hyperhydration for 7 days with fluid loading followed by cycling 
exercise bout in warm humid environment (30°C with 70% relative humidity) and 
the blood was withdrawn while subjects had seated for 6 minutes prior to the 
start of the endurance cycling test and ending with 40 min blood sample in same 
posture at the completion of the exercise bout. This supplementation for 7 days 
resulted in significant increases in body mass, TBW, ECW, ICW, serum osmolality 
with the attenuation of core temperature but did not succeed in expanding the 
plasma volume significantly (Easton et al., 2007).  
 
Upon the development of the first generation blood doping detection model the 
authors pointed out that Hct is an unreliable blood parameter and can be easily 
manipulated by postural effects and saline infusions (Parisotto et al., 2000a). 
This phenomenon of decreased and diluted Hct values was demonstrated and 
explained in EXP1, EXP2 and insignificantly in EXP3. UCI combined the 50% Hct 
value with the 17 g .L
-1 concentration cut-off for males instead of Hct alone to 
apply the “no-start” rule (UCI, 2009). Furthermore, FIS excluded Hct values from 
the  “start  prohibition”  rules  (FIS,  2009).  Upon  the  development  and 
establishment of the second generation blood doping detection model equations,  
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Hct was not included in any of the four ON and OFF model equations (Gore et 
al.,  2003).  Likewise,  the  third  generation  blood  doping  detection  model 
equations  included  mean  longitudinal  Hb  concentrations  and  OFF-hr  scores  
known as Z scores without any regard to Hct values (Sharpe et al., 2006). In 
EXP3,  none  of  Hb,  %Retics  or  OFF-hr  scores  were  affected  by  the 
supplementation protocol when blood was withdrawn from subjects resting in 
sitting  posture  for  10  min  before  or  after  exercise  and  did  not  result  in 
haemodilution.  
 
These findings emphasise the need for Gly to be ingested with Cr for the whole 7 
days of fluid hyperhydration loading period (as in  EXP1) and not only on the 
competition or test day (as in EXP3). The same protocol of Easton et al. (2007) 
was duplicated very recently in our laboratories and showed body mass gains up 
to 1.7 kg that represents increases in TBW. This suggests the use of both Cr and 
Gly in addition to carbohydrates for 7 days should  be implemented in future 
hyperhydration research aiming to increase TBW and expanding plasma volume. 
In  addition,  it  is  always  important  to  keep  in  mind  the  WADA’s  standards  in 
which  the  blood  sampling  should  be  in  sitting  posture  for  10  min  prior  to 
venipuncture. 
 
4.2. Conclusion 
 
The hyperhydration protocol of EXP1 using Cr and Gly for 7 days succeeded in 
significantly manipulating and increasing body mass, TBW, ECW, ICW and urine 
osmolality and decreasing Hct values but not Hb concentration when blood was 
withdrawn in supine (0°) posture. In EXP2, the change of posture from supine 
(0°), to sitting and ending with standing resulted  in haemoconcentration and 
increases in Hct and Hb values. When the approved posture of WADA, which is 
sitting for 10 min prior to blood sample withdrawal from subjects was applied in 
EXP3 with a slight change in hyperhydration protocol of Cr for 7 days and Gly on 
the seventh day only, it resulted in no significant changes in Hct, Hb, %Retics 
and OFF-hr scores and therefore no haemodilution effects when compared to 
pre-supplementation tests at rest and following submaximal exercise bouts in 
cool and warm environments. The hyperhydration protocol of EXP1 was more 
successful  in  decreasing  Hct  and  Hb  than  EXP3.  This  was  influenced  by  the  
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ingestion of a single bolus of Gly on the test day in EXP3 rather than a loading 
period of 7 days of Cr/Gly supplementation in EXP1 (fluid loading drink made up 
to 1 L twice daily for 6 days and once 5 hours prior to the first blood sample of 
the supplementation test day). In all three experiments (EXP1, EXP2 and EXP3), 
Hct among other blood parameters was the most affected by hyperhydration, 
posture and time at which blood samples were obtained. However, Hct is not a 
critical  blood  parameter  in  detecting  and  deterring  blood  doping  in  leading 
research or been published as such in peer-reviewed journals, nor has it been 
introduced  into  WADA’s  standards  or  adopted  by  federations  with  endurance 
athletes.  Moreover,  the  standardisation  of  blood  and  urine  samples  obtaining 
protocols of posture, time, altitudes and analytical methods play a decisive role 
in  which  substances  or  a  methods  are  considered  be  legal,  or  not,  in  the 
research area of doping in general. Upon the completion of these experiments 
(publication of the Easton et al., 2009 manuscript) and presentation to WADA, 
Gly was added to WADA’s prohibited substances list (The 2010 Prohibited List 
International standards, WADA, 2010;  Easton et al., 2009).  
 
More  research  is  required  to  recruit  more  endurance  athletes  with 
hyperhydration using Cr and Gly with fluid loading for 7 days at sea level as well 
as  at  altitude  with  WADA’s  approved  posture  and  time  of  blood  sample 
withdrawal. The addition of glucose to the Gly and Cr mix should be considered 
as it has been used in previous studies done within our laboratories (Easton et 
al.,  2006;    Easton  et  al.,  2007)  and  recently  unpublished  work  from  our 
laboratories that has resulted in substantial increases in body mass and provide 
hyperhydration results. 
 
More research is suggested to focus on markers and parameters that are affected 
by  blood  doping  methods  and  substances  which  are  very  difficult  to  detect 
without the incidences of false positives like autologous blood transfusions and r-
HuEPO injections and which are not susceptible to dilution and manipulation by 
masking methods and substances. Such markers could be certain genes that can 
be monitored and studied when they are activated or inhibited (switched on and 
off) by the use of these illegal blood doping substances and methods or other 
legal  scientific  proven  and  WADA  allowed  methods  like  living  or  training  at 
altitude.  
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